Document:

<PAGE>

                                                                     EXHIBIT 4.5

                                                                  EXECUTION COPY

                          EYETECH PHARMACEUTICALS, INC.

                              AMENDED AND RESTATED
                           INVESTORS' RIGHTS AGREEMENT

                                FEBRUARY 7, 2003

<PAGE>

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                                             Page
                                                                                                             ----
<S>                                                                                                          <C>
1.  Registration Rights.................................................................................       2
        1.1  Definitions................................................................................       2
        1.2  Request for Registration...................................................................       3
        1.3  Company Registration.......................................................................       4
        1.4  Form S-3 Registration......................................................................       5
        1.5  Obligations of the Company.................................................................       7
        1.6  Information from Holder....................................................................       9
        1.7  Expenses of Registration...................................................................       9
        1.8  Delay of Registration......................................................................       9
        1.9  Indemnification............................................................................      10
        1.10  Reports Under Securities Exchange Act of 1934.............................................      12
        1.11  Assignment of Registration Rights.........................................................      13
        1.12  Limitations on Subsequent Registration Rights.............................................      13
        1.13  "Market Stand-Off" Agreement..............................................................      13
        1.14  Termination of Registration Rights........................................................      14

2.  Covenants of the Company............................................................................      14
        2.1  Delivery of Financial Statements...........................................................      14
        2.2  Inspection.................................................................................      15
        2.3  Right of First Offer.......................................................................      15
        2.4  Stock Plan.................................................................................      17
        2.5  Compensation Committee.....................................................................      17
        2.6  Preservation of Corporate Existence........................................................      18
        2.7  Intellectual Property......................................................................      18
        2.8  Compliance with Laws.......................................................................      18
        2.9  Payment of Taxes...........................................................................      18
        2.10  Preservation of Property..................................................................      18
        2.11  Reservation of Shares.....................................................................      18
        2.12  Special Board Votes.......................................................................      19
        2.13  Termination of Certain Covenants..........................................................      19

3.  Covenants of the Investors..........................................................................      19
        3.1  Confidentiality............................................................................      19
        3.2  Public Announcements.......................................................................      19

4.  Miscellaneous.......................................................................................      20
        4.1  Successors and Assigns.....................................................................      20
        4.2  Governing Law..............................................................................      20
        4.3  Counterparts...............................................................................      20
        4.4  Titles and Subtitles.......................................................................      20
        4.5  Notices....................................................................................      20
        4.6  Expenses...................................................................................      21
        4.7  Entire Agreement: Amendments and Waivers...................................................      21
</TABLE>

                                       i

<PAGE>

<TABLE>
<S>                                                                                                   <C>
4.8  Severability...............................................................................      21
4.9  Aggregation of Stock.......................................................................      21
4.10  Termination of Prior Agreement............................................................      21
</TABLE>

                                       ii

<PAGE>

                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

                  THIS AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT (the
"AGREEMENT") is made as of the 7th day of February, 2003 by and among Eyetech
Pharmaceuticals, Inc., a Delaware corporation (the "COMPANY"), and the investors
listed on Schedule A hereto, each of which is herein referred to as an
"INVESTOR."

                                    RECITALS

                  WHEREAS, contemporaneously herewith, the Company and Pfizer
Ireland Pharmaceuticals (the "NEW INVESTOR") are parties to the Series D
Preferred Stock Purchase Agreement (the "SERIES D AGREEMENT"), which provides
for, among other things, the purchase by the New Investor of shares of the
Company's Series D Preferred Stock, $0.01 par value per share (the "SERIES D
PREFERRED STOCK"). The Series D Agreement contemplates that upon the occurrence
of certain events, the Company may issue another series of preferred stock to
the Subsequent Investor (as such term is defined in the Series D Agreement),
which is expected to be designated as Series E Preferred Stock (the "SERIES E
PREFERRED STOCK");

                  WHEREAS, certain of the Investors (the "EXISTING INVESTORS")
hold shares of the Company's Series A Preferred Stock, $0.01 par value per share
(the "SERIES A PREFERRED STOCK"), Series B Preferred Stock, $0.01 par value per
share (the "SERIES B PREFERRED STOCK"), Series C-1 Preferred Stock, $0.01 par
value per share (the "SERIES C-1 PREFERRED STOCK"), and Series C-2 Preferred
Stock, $0.01 par value per share (the "SERIES C-2 PREFERRED STOCK," and together
with the Series C-1 Preferred Stock, the "SERIES C PREFERRED STOCK") and/or
shares of Common Stock issued upon conversion thereof and possess registration
rights and other rights pursuant to an Investors' Rights Agreement dated as of
July 24, 2001 by and among the Company and the Existing Investors (the "PRIOR
AGREEMENT"). For purposes of this Agreement, the Series A Preferred Stock,
Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock
and, if issued, the Series E Preferred Stock are hereinafter sometimes referred
to as the "PREFERRED STOCK";

                  WHEREAS, one of the conditions to the closing of the sale of
the Series D Preferred Stock set forth in the Series D Agreement is that this
Agreement must be executed and delivered by Existing Investors holding at least
66 2/3% of the "REGISTRABLE SECURITIES" (as such term is defined in the Prior
Agreement) of the Company;

                  WHEREAS, in order to induce the Company and the Existing
Investors to approve the issuance of the Series D Preferred Stock, and to induce
the New Investor to enter into the Series D Agreement, the parties hereto hereby
agree that this Agreement shall govern the rights of the Investors to cause the
Company to register shares of Common Stock issued or issuable to them and
certain other matters as set forth herein; and

                  WHEREAS, the parties hereto (which parties include Existing
Investors holding at least 66 2/3% of the "REGISTRABLE SECURITIES" (as such term
is defined in the Prior Agreement)

<PAGE>

of the Company) desire to amend and restate the Prior Agreement and to grant to
the Investors the rights created pursuant hereto in lieu of the rights granted
to them under the Prior Agreement.

                  NOW, THEREFORE, in consideration of the mutual promises and
covenants set forth herein, the Existing Investors hereby agree that the Prior
Agreement shall be superseded and replaced in its entirety by this Agreement,
and the parties hereto further agree as follows:

                  1.       Registration Rights. The Company covenants and agrees
as follows:

                           1.1      Definitions. For purposes of this Section 1:

                           (a)      The term "ACT" means the Securities Act of
1933, as amended.

                           (b)      The term "FORM S-3" means such form under
the Act as in effect on the date hereof or any successor registration form under
the Act subsequently adopted by the SEC that permits inclusion or incorporation
of substantial information by reference to other documents filed by the Company
with the SEC.

                           (c)      The term "HOLDER" means the Investors and
any successor to, assignee of or transferee of Registrable Securities held by
such Investors in accordance with Section 1.11 hereof;

                           (d)      The term "INITIAL OFFERING" means the
Company's first firm commitment underwritten public offering of its Common Stock
under the Act.

                           (e)      The term "1934 ACT" means the Securities
Exchange Act of 1934, as amended.

                           (f)      The terms "REGISTER," "REGISTERED," and
"REGISTRATION" refer to a registration effected by preparing and filing a
registration statement or similar document in compliance with the Act, and the
declaration or ordering of effectiveness of such registration statement or
document.

                           (g)      The term "REGISTRABLE SECURITIES" means (i)
the Common Stock issuable or issued upon conversion of the Series A Preferred
Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred
Stock and, if issued pursuant to the terms of the Series D Agreement, the Series
E Preferred Stock, and (ii) any Common Stock of the Company issued as (or
issuable upon the conversion or exercise of any warrant, right or other security
that is issued as) a dividend or other distribution with respect to, or in
exchange for, or in replacement of, the shares referenced in subsection (i)
above, excluding in all cases, however, any Registrable Securities sold by a
person in a transaction in which his, her or its rights under this Section 1 are
not assigned.

                           (h)      The number of shares of "REGISTRABLE
SECURITIES" outstanding shall be determined by the number of shares of Common
Stock outstanding that are, and the number of shares of Common Stock issuable
pursuant to then exercisable or convertible securities that are, Registrable
Securities.

                                       2

<PAGE>

                           (i)      The term "SEC" means the Securities and
Exchange Commission.

                  1.2      Request for Registration.

                           (a)      Subject to the conditions of this Section
1.2, if the Company shall receive at any time after six (6) months after the
effective date of the Initial Offering, a written request from the Holders of
thirty-five percent (35%) or more of the Registrable Securities then outstanding
(the "INITIATING HOLDERS") that the Company file a registration statement under
the Act covering the registration of Registrable Securities with an anticipated
aggregate offering price to the public (net of any underwriters' discounts or
commissions) of at least $10,000,000, then the Company shall, within twenty (20)
days of the receipt thereof, give written notice of such request to all Holders,
and subject to the limitations of this Section 1.2, use all reasonable efforts
to effect, as soon as practicable, the registration under the Act of all
Registrable Securities that the Holders request to be registered in a written
request received by the Company within twenty (20) days of the mailing of the
Company's notice pursuant to this Section 1.2(a).

                           (b)      If the Initiating Holders intend to
distribute the Registrable Securities covered by their request by means of an
underwriting, they shall so advise the Company as a part of their request made
pursuant to this Section 1.2 and the Company shall include such information in
the written notice referred to in Section 1.2(a). In such event the right of any
Holder to include its Registrable Securities in such registration shall be
conditioned upon such Holder's participation in such underwriting and the
inclusion of such Holder's Registrable Securities in the underwriting (unless
otherwise mutually agreed by a majority in interest of the Initiating Holders
and such Holder) to the extent provided herein. All Holders proposing to
distribute their securities through such underwriting shall enter into an
underwriting agreement in reasonable and customary form with the underwriter or
underwriters selected for such underwriting by a majority in interest of such
Holders (which underwriter or underwriters shall be reasonably acceptable to the
Company). Notwithstanding any other provision of this Section 1.2, if the
underwriter advises the Company that marketing factors require a limitation of
the number of securities underwritten (including Registrable Securities), then
the Company shall so advise all Holders of Registrable Securities that would
otherwise be underwritten pursuant hereto, and the number of shares that may be
included in the underwriting shall be allocated to the Holders of such
Registrable Securities on a pro rata basis based on the number of Registrable
Securities originally requested to be included in such registration by such
Holders. Any Registrable Securities excluded or withdrawn from such underwriting
shall be withdrawn from the registration.

                           (c)      The Company shall not be required to effect
a registration pursuant to this Section 1.2:

                                    (i)      in any particular jurisdiction in
which the Company would be required to execute a general consent to service of
process in effecting such registration, unless the Company is already subject to
service in such jurisdiction and except as may be required under the Act;

                                       3

<PAGE>

                                    (ii)     after the Company has effected
three (3) registrations pursuant to this Section 1.2, and such registrations
have been declared or ordered effective; provided, however, that any
registrations in which the Holders were unable to sell at least 50% of the
Registrable Securities requested to be included therein shall not count for
purposes of this clause (ii);

                                    (iii)    during the period starting with the
date sixty (60) days prior (the "STARTING DATE") to the Company's good faith
estimate of the date of the filing of, and ending on the earlier to occur of (A)
the date that is ninety (90) days after the effective date or (B) a date not to
exceed one hundred fifty (150) days after the Starting Date, a Company-initiated
registration subject to Section 1.3 below, provided, however, that with respect
to the Company's Initial Offering, such period shall be one hundred eighty (180)
days, and provided, further, that the Company is actively employing in good
faith all reasonable efforts to cause such registration statement to become
effective;

                                    (iv)     if the Initiating Holders propose
to dispose of Registrable Securities that may be registered on Form S-3 pursuant
to Section 1.4 hereof; or

                                    (v)      if the Company shall furnish to
Holders requesting a registration statement pursuant to this Section 1.2, a
certificate signed by the Company's Chief Executive Officer or Chairman of the
Board stating that in the good faith judgment of the Board of Directors of the
Company, it would be seriously detrimental to the Company and its shareholders
for such registration statement to be effected at such time, in which event the
Company shall have the right to defer such filing for a period of not more than
ninety (90) days after receipt of the request of the Initiating Holders,
provided that such right to delay a request shall be exercised by the Company
not more than once in any twelve (12) month period.

                  1.3      Company Registration.

                           (a)      If (but without any obligation to do so) the
Company proposes to register (including for this purpose a registration effected
by the Company for shareholders other than the Holders) any of its stock or
other securities under the Act in connection with the public offering of such
securities (other than a registration relating solely to the sale of securities
to participants in a Company stock plan, a registration relating to a corporate
reorganization or other transaction under Rule 145 of the Act, a registration on
any form that does not include substantially the same information as would be
required to be included in a registration statement covering the sale of the
Registrable Securities, or a registration in which the only Common Stock being
registered is Common Stock issuable upon conversion of debt securities that are
also being registered), the Company shall, at such time, promptly give each
Holder written notice of such registration. Upon the written request of each
Holder given within twenty (20) days after delivery of such notice by the
Company in accordance with Section 4.5, the Company shall, subject to the
provisions of Section 1.3(c), use all reasonable efforts to cause to be
registered under the Act all of the Registrable Securities that each such Holder
(all such Holders collectively referred to herein as the "SELLING HOLDERS") has
requested to be registered.

                                       4

<PAGE>

                           (b)      Right to Terminate Registration. The Company
shall have the right to terminate or withdraw any registration initiated by it
under this Section 1.3 prior to the effectiveness of such registration whether
or not any Holder has elected to include securities in such registration. The
expenses of such withdrawn registration shall be borne by the Company in
accordance with Section 1.7 hereof.

                           (c)      Underwriting Requirements. In connection
with any offering involving an underwriting of shares of the Company's capital
stock, the Company shall not be required under this Section 1.3 to include any
of the Selling Holders' securities in such underwriting unless they accept the
terms of the underwriting as negotiated in good faith and agreed upon between
the Company and the underwriters selected by it (or by other persons entitled to
select the underwriters) and enter into an underwriting agreement in reasonable
and customary form with an underwriter or underwriters selected by the Company,
and then only in such quantity as the underwriters determine in their sole
discretion will not jeopardize the success of the offering by the Company. If
the total amount of securities, including Registrable Securities, requested by
shareholders to be included in such offering exceeds the amount of securities
sold other than by the Company that the underwriters determine in their sole
discretion is compatible with the success of the offering, then the Company
shall be required to include in the offering only that number of such
securities, including Registrable Securities, that the underwriters determine in
their sole discretion will not jeopardize the success of the offering (the
securities so included to be apportioned pro rata among the Selling Holders
according to the total amount of securities requested to be included therein by
each Selling Holder or in such other proportions as shall mutually be agreed to
by such Selling Holders), but in no event shall the amount of securities of the
Selling Holders included in the offering be reduced below thirty percent (30%)
of the total amount of securities included in such offering, unless such
offering is the initial public offering of the Company's securities, in which
case the Selling Holders may be excluded if the underwriters make the
determination described above and no other shareholder's securities are
included. For purposes of the preceding parenthetical concerning apportionment,
for any selling shareholder that is a Holder of Registrable Securities and that
is a partnership, limited liability company or corporation, the partners,
retired partners, members, retired members and shareholders of such Holder, or
the estates and family members of any such partners, retired partners, members,
retired members and any trusts for the benefit of any of the foregoing persons
shall be deemed to be a single "SELLING HOLDER," and any pro rata reduction with
respect to such "SELLING HOLDER" shall be based upon the aggregate amount of
Registrable Securities owned by all such related entities and individuals.

                  1.4      Form S-3 Registration. In case the Company shall
receive from the Holders of at least twenty-five percent (25%) of the
Registrable Securities a written request or requests that the Company effect a
registration on Form S-3 and any related qualification or compliance with
respect to all or a part of the Registrable Securities owned by such Holder or
Holders, the Company shall:

                           (a)      promptly give written notice of the proposed
registration, and any related qualification or compliance, to all other Holders;
and

                           (b)      use all reasonable efforts to effect, as
soon as practicable, such registration and all such qualifications and
compliances as may be so requested and as

                                       5

<PAGE>

would permit or facilitate the sale and distribution of all or such portion of
such Holders' Registrable Securities as are specified in such request, together
with all or such portion of the Registrable Securities of any other Holders
joining in such request as are specified in a written request given within
twenty (20) days after receipt of such written notice from the Company,
provided, however, that the Company shall not be obligated to effect any such
registration, qualification or compliance, pursuant to this Section 1.4:

                                    (i)      if Form S-3 is not available for
such offering by the Holders;

                                    (ii)     if the Holders, together with the
holders of any other securities of the Company entitled to inclusion in such
registration, propose to sell Registrable Securities and such other securities
(if any) at an aggregate price to the public (net of any underwriters' discounts
or commissions) of less than $3,000,000;

                                    (iii)    if the Company shall furnish to the
Holders a certificate signed by the Chief Executive Officer or Chairman of the
Board of the Company stating that in the good faith judgment of the Board of
Directors of the Company, it would be seriously detrimental to the Company and
its shareholders for such Form S-3 Registration to be effected at such time, in
which event the Company shall have the right to defer the filing of the Form S-3
registration statement for a period of not more than ninety (90) days after
receipt of the request of the Holder or Holders under this Section 1.4;
provided, however, that the Company shall not utilize this right more than once
in any twelve (12) month period; or

                                    (iv)     if the Company has, within the
twelve (12) month period preceding the date of such request, already effected
two (2) registrations on Form S-3 for the Holders pursuant to this Section 1.4.

                           (c)      Notwithstanding the foregoing, the Company
shall not be obligated to:

                                    (i)      cause a registration on Form S-3 to
become effective prior to ninety (90) days following the effective date of a
Company-initiated registration (other than a registration effected solely to
qualify an employee benefit plan or to effect a business combination pursuant to
Rule 145);

                                    (ii)     cause a registration on Form S-3 to
become effective prior to expiration of ninety (90) days following the effective
date of the most recent registration pursuant to a request under Section 1.2 of
this Agreement or pursuant to a request by a holder of registration rights under
any other agreement of the Company granting Form S-3 demand registration rights
in which the Holders were given the opportunity to participate;

                                    (iii)    cause a registration on Form S-3 to
become effective prior to one hundred eighty (180) days following the effective
date of a registration initiated by the holders of Registrable Securities under
this Section 1.4; or

                                    (iv)     maintain and keep any such
registration on Form S-3 effective after the shorter of (A) ninety (90) days
from the effective date of such registration

                                       6

<PAGE>

statement or (B) that time reasonably necessary to permit the disposition of the
Registrable Securities subject to such registration. Subject to the foregoing,
the Company will use all reasonable efforts to effect promptly the registration
of all shares of Registrable Securities on Form S-3 to the extent requested by
the Holder or Holders thereof for purposes of disposition. In the event that the
Company determines that market factors require a limitation on the number of
shares to be underwritten, then shares shall be excluded from such registration
and underwriting pursuant to the method described in Section 1.3(c).

                           (d)      Subject to the foregoing, the Company shall
file a registration statement covering the Registrable Securities and other
securities so requested to be registered as soon as practicable after receipt of
the request or requests of the Holders. Registrations effected pursuant to this
Section 1.4 shall not be counted as requests for registration effected pursuant
to Sections 1.2.

                  1.5      Obligations of the Company. Whenever required under
this Section 1 to effect the registration of any Registrable Securities, the
Company shall use all reasonable efforts to, as expeditiously as reasonably
possible:

                           (a)      prepare and file with the SEC a registration
statement with respect to such Registrable Securities and use all reasonable
efforts to cause such registration statement to become effective, and keep such
registration statement effective for a period of up to ninety (90) days or, if
earlier, until the distribution contemplated in the Registration Statement has
been completed;

                           (b)      furnish, at least five (5) days before
filing a registration statement that registers such Registrable Securities, a
draft prospectus relating thereto and any amendments or supplements (if any)
relating to such registration statement or prospectus, to one (1) counsel
selected by Holders of a majority of the Registrable Securities (other than the
New Investor) covered by such registration statement (the "STOCKHOLDERS'
COUNSEL") and to counsel selected by the New Investor if it is then still a
holder of Registrable Securities copies of all such documents proposed to be
filed (it being understood that such five (5) day period need not apply to
successive drafts of the same document proposed to be filed so long as such
successive drafts are supplied to Stockholders' Counsel in advance of the
proposed filing by a period of time that is customary under the circumstances);

                           (c)      notify Stockholders' Counsel promptly in
writing (i) of any comments by the SEC with respect to such registration
statement or prospectus, or any request by the SEC for the amending or
supplementing thereof or for additional information with respect thereto, (ii)
of the issuance by the SEC of any stop order suspending the effectiveness of
such registration statement or prospectus or any amendment or supplement thereto
or the initiation of any proceedings for that purpose and (iii) of the receipt
by the Company of any notification with respect to the suspension of the
qualification of such Registrable Securities for sale in any jurisdiction;

                           (d)      prepare and file with the SEC such
amendments and supplements to such registration statement and the prospectus
used in connection with such

                                       7

<PAGE>

registration statement as may be necessary to comply with the provisions of the
Act with respect to the disposition of all securities covered by such
registration statement;

                           (e)      furnish to each Holder such numbers of
copies of a prospectus, including a preliminary prospectus, in conformity with
the requirements of the Act, and such other documents as such Holder may
reasonably request in order to facilitate the disposition of Registrable
Securities owned by such Holder;

                           (f)      use all reasonable efforts to register and
qualify the securities covered by such registration statement under such other
securities or Blue Sky laws of such jurisdictions as shall be reasonably
requested by any Holder, provided that the Company shall not be required in
connection therewith or as a condition thereto to qualify to do business or to
file a general consent to service of process in any such states or jurisdictions
where it would not otherwise be required to do so but for this subsection (f);

                           (g)      in the event of any underwritten public
offering, enter into and perform its obligations under an underwriting
agreement, in reasonable and customary form, with the managing underwriter of
such offering;

                           (h)      use all reasonable efforts to cause such
Registrable Securities to be registered with or approved by such other
governmental authorities as may be necessary by virtue of the business and
operations of the Company to enable the seller or sellers thereof to consummate
the disposition of such Registrable Securities;

                           (i)      notify on a timely basis each Holder of
Registrable Securities covered by such registration statement at any time when a
prospectus relating thereto is required to be delivered under the Act or the
happening of any event as a result of which the prospectus included in such
registration statement, as then in effect, includes an untrue statement of a
material fact or omits to state a material fact required to be stated therein or
necessary to make the statements therein not misleading in the light of the
circumstances then existing and, at the request of such seller, prepare and
furnish to such seller a reasonable number of such copies of a supplement or
amendment of such prospectus as may be necessary so that, as thereafter
delivered to the offerees of such shares, such prospectus shall not include an
untrue statement of material fact or omit to state a material fact required to
be stated therein or necessary to make the statements therein not misleading in
light of the circumstances then existing;

                           (j)      cause all such Registrable Securities
registered pursuant hereunder to be listed on each national securities exchange
on which similar securities issued by the Company are then listed, or, if the
securities of the Company are not listed on a national securities exchange, use
all reasonable efforts to qualify such Registrable Securities for inclusion on
the automated quotation system of the National Association of Securities
Dealers, Inc., National Market System, or such other national securities
exchange as the holders of a majority of such Registrable Securities included in
such registration shall request;

                           (k)      provide a transfer agent and registrar for
all Registrable Securities registered pursuant hereunder and a CUSIP number for
all such Registrable Securities, in each case not later than the effective date
of such registration;

                                       8

<PAGE>

                           (l)      make available for inspection by any seller
of Registrable Securities all pertinent financial, business and other documents
and records of the Company, and to use all reasonable efforts to cause the
Company's employees, officers and directors to supply all information reasonably
requested by any such seller in connection with the preparation of such
registration statement; provided, however, that the Company shall not be
obligated pursuant to this Section 1.5(l) to provide access to any information
that it reasonably considers to be a trade secret or similar confidential
information;

                           (m)      use all reasonable efforts to obtain from
its independent certified public accountants a "COLD COMFORT" letter in
customary form and covering such matters of the type customarily covered by cold
comfort letters (which shall be addressed to the underwriters, with a copy sent
to each of the Holders selling Registrable Securities in such registration); and

                           (n)      use all reasonable efforts to obtain from
its counsel an opinion or opinions in customary form (which shall also be
addressed to the underwriters, with a copy sent to each of the Holders selling
Registrable Securities in such registration).

                  1.6      Information from Holder. It shall be a condition
precedent to the obligations of the Company to take any action pursuant to this
Section 1 with respect to the Registrable Securities of any Selling Holder that
such Holder shall furnish to the Company and the managing underwriter such
information regarding itself, the Registrable Securities held by it, and the
intended method of disposition of such securities as shall be required to effect
the registration of such Holder's Registrable Securities.

                  1.7      Expenses of Registration. All expenses other than
underwriting discounts and commissions incurred in connection with
registrations, filings or qualifications pursuant to Sections 1.2, 1.3 and 1.4,
including (without limitation) all registration, filing and qualification fees,
printers' and accounting fees, fees and disbursements of counsel for the Company
and the reasonable fees and disbursements of the Stockholders' Counsel shall be
borne by the Company. Notwithstanding the foregoing, the Company shall not be
required to pay for any expenses of any registration proceeding begun pursuant
to Section 1.2 if the registration request is subsequently withdrawn at the
request of the Initiating Holders holding a majority of the Registrable
Securities held by such Initiating Holders (in which case all participating
Holders shall bear such expenses pro rata based upon the number of Registrable
Securities that were requested to be registered in the withdrawn registration)
and such withdrawn registration shall not count as a registration under Section
1.2 for the purposes of subsection 1.2(c)(ii), unless, in the case of a
registration requested under Section 1.2, the Holders of a majority of the
Registrable Securities agree to forfeit their right to one demand registration
pursuant to Section 1.2, provided, however, that if at the time of such
withdrawal, the Holders have learned of a material adverse change in the
condition, business, or prospects of the Company from that known to the Holders
at the time of their request and have withdrawn the request with reasonable
promptness as a result thereof, then the Holders shall not be required to pay
any of such expenses and shall retain their rights pursuant to Section 1.2 or
1.4.

                  1.8      Delay of Registration. No Holder shall have any right
to obtain or seek an injunction restraining or otherwise delaying any such
registration as the result of any

                                       9

<PAGE>

controversy that might arise with respect to the interpretation or
implementation of this Section 1.

                  1.9      Indemnification. In the event any Registrable
Securities are included in a registration statement under this Section 1:

                           (a)      To the extent permitted by law, the Company
will indemnify and hold harmless each Holder, the partners or officers,
directors and shareholders of each Holder, legal counsel and accountants for
each Holder, any underwriter (as defined in the Act) for such Holder and each
person, if any, who controls such Holder or underwriter within the meaning of
the Act or the 1934 Act, against any losses, claims, damages or liabilities
(joint or several) to which they may become subject under the Act, the 1934 Act
or any state securities laws, insofar as such losses, claims, damages, or
liabilities (or actions in respect thereof) arise out of or are based upon any
of the following statements, omissions or violations (collectively a
"VIOLATION"): (i) any untrue statement or alleged untrue statement of a material
fact contained in such registration statement, including any preliminary
prospectus or final prospectus contained therein or any amendments or
supplements thereto, (ii) the omission or alleged omission to state therein a
material fact required to be stated therein, or necessary to make the statements
therein not misleading, or (iii) any violation or alleged violation by the
Company of the Act, the 1934 Act, any state securities laws or any rule or
regulation promulgated under the Act, the 1934 Act or any state securities laws;
and the Company will promptly reimburse, as incurred, each such Holder,
underwriter, controlling person or other indemnified person for any legal or
other expenses reasonably incurred by them in connection with investigating or
defending any such loss, claim, damage, liability or action; provided, however,
that the indemnity agreement contained in this subsection l.9(a) shall not apply
to amounts paid in settlement of any such loss, claim, damage, liability or
action if such settlement is effected without the consent of the Company (which
consent shall not be unreasonably withheld), nor shall the Company be liable in
any such case for any such loss, claim, damage, liability or action to the
extent that it arises out of or is based upon a Violation that occurs in
reliance upon and in conformity with written information furnished expressly for
use in connection with such registration by any such Holder, underwriter or
controlling person; provided, further, however, that the foregoing indemnity
agreement with respect to any preliminary prospectus shall not inure to the
benefit of any Holder or underwriter, or any person controlling such Holder or
underwriter, from whom the person asserting any such losses, claims, damages or
liabilities purchased shares in the offering, if a copy of the prospectus (as
then amended or supplemented if the Company shall have timely furnished any
amendments or supplements thereto) was not sent or given by or on behalf of such
Holder or underwriter to such person, if required by law so to have been
delivered, at or prior to the written confirmation of the sale of the shares to
such person, and if the prospectus (as so amended or supplemented) would have
cured the defect giving rise to such loss, claim, damage or liability.

                           (b)      To the extent permitted by law, each Selling
Holder, severally and not jointly, will indemnify and hold harmless the Company,
each of its directors, each of its officers who has signed the registration
statement, each person, if any, who controls the Company within the meaning of
the Act, legal counsel and accountants for the Company, any underwriter, any
other Holder selling securities in such registration statement, legal counsel
and accountants for such other Holder and any controlling person of any such
underwriter or other

                                       10

<PAGE>

Holder, against any losses, claims, damages or liabilities (joint or several) to
which any of the foregoing persons may become subject, under the Act, the 1934
Act or any state securities laws, insofar as such losses, claims, damages or
liabilities (or actions in respect thereto) arise out of or are based upon any
Violation, in each case to the extent (and only to the extent) that such
Violation occurs in reliance upon and in conformity with written information
furnished by such Holder expressly for use in connection with such registration;
and each such Holder will reimburse any person intended to be indemnified
pursuant to this subsection l.9(b) for any legal or other expenses reasonably
incurred by such person in connection with investigating or defending any such
loss, claim, damage, liability or action; provided, however, that the indemnity
agreement contained in this subsection l.9(b) shall not apply to amounts paid in
settlement of any such loss, claim, damage, liability or action if such
settlement is effected without the consent of the Holder (which consent shall
not be unreasonably withheld), provided, further, that in no event shall any
indemnity under this subsection l.9(b) exceed the net proceeds from the offering
received by such Holder.

                           (c)      Promptly after receipt by an indemnified
party under this Section 1.9 of notice of the commencement of any action
(including any governmental action), such indemnified party will, if a claim in
respect thereof is to be made against any indemnifying party under this Section
1.9, deliver to the indemnifying party a written notice of the commencement
thereof and the indemnifying party shall have the right to participate in, and,
to the extent the indemnifying party so desires, jointly with any other
indemnifying party similarly noticed, to assume the defense thereof with counsel
mutually satisfactory to the parties, and after notice from the indemnifying
party to such indemnified party of its election to so assume the defense
thereof, the indemnifying party shall not be responsible for any legal or other
expenses subsequently incurred by the indemnified party in connection therewith;
provided, however, that an indemnified party (together with all other
indemnified parties that may be represented without conflict by one counsel)
shall have the right to retain one separate counsel, with the fees and expenses
to be paid by the indemnifying party, if representation of such indemnified
party by the counsel retained by the indemnifying party would be inappropriate
due to actual or potential differing interests between such indemnified party
and any other party represented by such counsel in such proceeding. The failure
to deliver written notice to the indemnifying party within a reasonable time of
the commencement of any such action, if (and only to the extent that it is)
materially prejudicial to its ability to defend such action, shall relieve such
indemnifying party of liability to such extent to the indemnified party under
this Section 1.9, but the omission to so deliver written notice to the
indemnifying party will not relieve it of any liability that it may have to any
indemnified party otherwise than under this Section 1.9. No indemnifying party,
in the defense of any such claim or litigation, shall, except with the consent
of each indemnified party, which consent shall not be unreasonably withheld,
consent to entry of any judgment or enter into any settlement which does not
include as an unconditional term thereof the giving by the claimant or plaintiff
to such indemnified party of a release from all liability in respect to such
claim or litigation, provided that no indemnifying party shall, without the
prior written consent of the indemnified party, agree to the entry of any
judgment, settlement, compromise or decree that provides for injunctive or other
nonmonetary relief affecting the indemnified party.

                           (d)      If the indemnification provided for in this
Section 1.9 is held by a court of competent jurisdiction to be unavailable to an
indemnified party with respect to any loss, liability, claim, damage or expense
referred to herein, then the indemnifying party, in

                                       11

<PAGE>

lieu of indemnifying such indemnified party hereunder, shall contribute to the
amount paid or payable by such indemnified party as a result of such loss,
liability, claim, damage or expense in such proportion as is appropriate to
reflect the relative fault of the indemnifying party on the one hand and of the
indemnified party on the other in connection with the statements or omissions
that resulted in such loss, liability, claim, damage or expense, as well as any
other relevant equitable considerations; provided, however, that the maximum
amount of liability in respect of such contribution shall be limited, in the
case of each seller of Registrable Shares, to an amount equal to the net
proceeds received by such seller from the sale of Registrable Securities
effected pursuant to such registration. The relative fault of the indemnifying
party and of the indemnified party shall be determined by reference to, among
other things, whether the untrue or alleged untrue statement of a material fact
or the omission to state a material fact relates to information supplied by the
indemnifying party or by the indemnified party and the parties' relative intent,
knowledge, access to information, and opportunity to correct or prevent such
statement or omission.

                           (e)      Notwithstanding the foregoing, to the extent
that the provisions on indemnification and contribution contained in the
underwriting agreement entered into in connection with the underwritten public
offering are in conflict with the foregoing provisions, the provisions in the
underwriting agreement shall control.

                           (f)      The obligations of the Company and Holders
under this Section 1.9 shall survive the completion of any offering of
Registrable Securities in a registration statement under this Section 1, and
otherwise.

                  1.10     Reports Under Securities Exchange Act of 1934. With a
view to making available to the Holders the benefits of Rule 144 promulgated
under the Act and any other rule or regulation of the SEC that may at any time
permit a Holder to sell securities of the Company to the public without
registration or pursuant to a registration on Form S-3, the Company agrees to
use all reasonable efforts to:

                           (a)      make and keep public information available,
as those terms are understood and defined in SEC Rule 144, at all times after
the effective date of the Initial Offering;

                           (b)      file with the SEC in a timely manner all
reports and other documents required of the Company under the Act and the 1934
Act; and

                           (c)      furnish to any Holder, so long as the Holder
owns any Registrable Securities, forthwith upon request (i) a written statement
by the Company that it has complied with the reporting requirements of SEC Rule
144 (at any time after the effective date of the first registration statement
filed by the Company), the Act and the 1934 Act (at any time after it has become
subject to such reporting requirements), or that it qualifies as a registrant
whose securities may be resold pursuant to Form S-3 (at any time after it so
qualifies), (ii) a copy of the most recent annual or quarterly report of the
Company and such other reports and documents so filed by the Company, and (iii)
such other information as may be reasonably requested in availing any Holder of
any rule or regulation of the SEC that permits the selling of any such
securities without registration or pursuant to such form.

                                       12

<PAGE>

                  1.11     Assignment of Registration Rights. Provided that the
Company is given prior written notice of such assignment, the rights to cause
the Company to register Registrable Securities pursuant to this Section 1 may be
assigned (but only with all related obligations) by a Holder to a transferee or
assignee of such securities that (i) is a subsidiary, parent, partner, limited
partner, retired partner, shareholder, other affiliate or entity under common
investment management of a Holder, (ii) is a Holder's family member or trust for
the benefit of an individual Holder, or (iii) after such assignment or transfer,
holds the lesser of (A) shares of Registrable Securities with an aggregate
original purchase price of $1,000,000 or (B) at least fifty percent (50%) of the
shares of Registrable Securities originally issued to such transferor or
assignor (subject to appropriate adjustment for stock splits, stock dividends,
combinations and other recapitalizations), provided, that: (a) the Company is,
within a reasonable time after such transfer, furnished with written notice of
the name and address of such transferee or assignee and the securities with
respect to which such registration rights are being assigned; (b) such
transferee or assignee agrees in writing to be bound by and subject to the terms
and conditions of this Agreement, including without limitation the provisions of
Section 1.13 below; and (c) such assignment shall be effective only if
immediately following such transfer the further disposition of such securities
by the transferee or assignee is restricted under the Act.

                  1.12     Limitations on Subsequent Registration Rights. From
and after the date of this Agreement, the Company shall not, without the prior
written consent of the Holders of a majority of the Registrable Securities (the
"Consenting Holders"), enter into any agreement with any holder or prospective
holder of any securities of the Company that would allow such holder or
prospective holder (a) to include such securities in any registration filed
under Section 1.3 hereof, unless under the terms of such agreement, such holder
or prospective holder may include such securities in any such registration only
to the extent that the inclusion of such securities will not reduce the amount
of the Registrable Securities of the Holders that are included or (b) to demand
registration of their securities; it being understood and agreed that the
Consenting Holders shall not be permitted to consent to any grant of subsequent
registration rights described in clauses (a) or (b) of this Section 1.12 which
would treat any Holder in a manner different from the Consenting Holders,
without the consent of the Holder so affected.

                  1.13     "Market Stand-Off" Agreement. Each Holder hereby
agrees that it will not, without the prior written consent of the managing
underwriter, during the period commencing on the date of the final prospectus
relating to the Company's Initial Offering and ending on the date specified by
the Company and the managing underwriter (such period not to exceed one hundred
eighty (l80) days) (i) lend, offer, pledge, sell, contract to sell, sell any
option or contract to purchase, purchase any option or contract to sell, grant
any option, right or warrant to purchase, or otherwise transfer or dispose of,
directly or indirectly, any shares of Common Stock or any securities convertible
into or exercisable or exchangeable for Common Stock (whether such shares or any
such securities are then owned by the Holder or are thereafter acquired), or
(ii) enter into any swap or other arrangement that transfers to another, in
whole or in part, any of the economic consequences of ownership of the Common
Stock, whether any such transaction described in clause (i) or (ii) above is to
be settled by delivery of Common Stock or such other securities, in cash or
otherwise. Notwithstanding anything to the contrary above, a Holder may transfer
to its affiliates shares of Common Stock or any securities convertible into or
exercisable or exchangeable for Common Stock within the period specified

                                       13

<PAGE>

above, provided such transfer is made in accordance with Section 3.7 of the
Series D Agreement (with respect to transfers of Series D Preferred Stock or
Series E Preferred Stock or the Common Stock issuable upon conversion thereof)
or the comparable provisions of the purchase agreement pursuant to which the
Existing Investors acquired their securities from the Company (with respect to
transfers of Preferred Stock (other than Series D Preferred Stock or Series E
Preferred Stock) and other securities exercisable for such Preferred Stock, or
Common Stock issuable upon conversion or exercise thereof). The foregoing
provisions of this Section 1.13 shall apply only to the Company's initial public
offering of equity securities, shall not apply to the sale of any shares to an
underwriter pursuant to an underwriting agreement, and shall only be applicable
to the Holders if all officers and directors and greater than one percent (1%)
shareholders of the Company enter into similar agreements. Any discretionary
waiver or termination by the Company or representative of the underwriters of
the restrictions in this Section 1.13 shall apply to all persons subject to such
restrictions pro rata based on the number of shares of Common Stock (and/or
shares of Common Stock into which such Registrable Shares are convertible)
subject to such restrictions.

         The underwriters in connection with the Company's initial public
offering are intended third party beneficiaries of this Section 1.13 and shall
have the right, power and authority to enforce the provisions hereof as though
they were a party hereto. In order to enforce the foregoing covenant, the
Company may impose stop-transfer instructions with respect to the Registrable
Securities of each Holder (and the shares or securities of every other person
subject to the foregoing restriction) until the end of such period.
Notwithstanding anything to the contrary in this Section 1.13, a Holder that is
an entity whose business consists primarily of investing and trading securities
shall not be restricted by this Section 1.13 in trading securities of the
Company (that are not otherwise Registrable Shares hereunder) that such Holder
acquires in or after the Company's initial public offering.

                  1.14     Termination of Registration Rights. No Holder shall
be entitled to exercise any right provided for in this Section 1 after five (5)
years following the consummation of the Initial Offering or, as to any Holder,
such earlier time at which all Registrable Securities held by such Holder (and
any affiliate of the Holder with whom such Holder must aggregate its sales under
Rule 144) can be sold in any three (3) month period without registration in
compliance with Rule 144 of the Act.

         2.       Covenants of the Company.

                  2.1      Delivery of Financial Statements. The Company shall
deliver to each Investor:

                           (a)      as soon as practicable, but in any event
within ninety (90) days after the end of each fiscal year of the Company, an
income statement for such fiscal year, a balance sheet of the Company and
statement of shareholder's equity as of the end of such year, and a statement of
cash flows for such year, such year-end financial reports to be in reasonable
detail, prepared in accordance with generally accepted accounting principles
("GAAP"), and audited and certified by independent public accountants of
nationally recognized standing selected by the Company;

                                       14

<PAGE>

                           (b)      as soon as practicable, but in any event
within forty-five (45) days after the end of each of the first three (3)
quarters of each fiscal year of the Company, an unaudited income statement,
statement of cash flows for such fiscal quarter and an unaudited balance sheet
as of the end of such fiscal quarter;

                           (c)      upon request, within forty-five (45) days of
the end of each month, an unaudited income statement and statement of cash flows
and balance sheet for and as of the end of such month, in reasonable detail;

                           (d)      as soon as practicable, but in any event at
least thirty (30) days prior to the end of each fiscal year, a budget and
business plan for the next fiscal year, prepared on a monthly basis, including
balance sheets, income statements and statements of cash flows for such months
and, as soon as prepared, any other budgets or revised budgets prepared by the
Company;

                           (e)      with respect to the financial statements
called for in subsections (b)and (c) of this Section 2.1, an instrument executed
by the Chief Financial Officer or President of the Company certifying that such
financials were prepared in accordance with GAAP consistently applied with prior
practice for earlier periods (with the exception of footnotes that may be
required by GAAP) and fairly present the financial condition of the Company and
its results of operation for the period specified, subject to year-end audit
adjustment; and

                           (f)      such other information relating to the
financial condition, business, prospects or corporate affairs of the Company as
the Investor or any assignee of the Investor may from time to time request,
provided, however, that the Company shall not be obligated under this subsection
(f) or any other subsection of this Section 2.1 to provide information that it
deems in good faith to be a trade secret or similar confidential information.

                  2.2      Inspection. The Company shall permit each Investor
that holds shares of Preferred Stock (and/or Common Stock issued upon conversion
thereof) with an aggregate original purchase price of $1,000,000 to visit and
inspect the Company's properties, to examine its books of account and records
and to discuss the Company's affairs, finances and accounts with its officers,
all at such reasonable times as may be requested by the Investor; provided,
however, that the Company shall not be obligated pursuant to this Section 2.2 to
provide access to any information that it reasonably considers to be a trade
secret or similar confidential information.

                  2.3      Right of First Offer. Subject to the terms and
conditions specified in this Section 2.3, the Company hereby grants to each
Major Investor (as hereinafter defined) a right of first offer with respect to
future sales by the Company of its Shares (as hereinafter defined). For purposes
of this Section 2.3, a Major Investor shall mean any Investor or transferee that
holds shares of Preferred Stock (or the Common Stock issued upon conversion
thereof) with an aggregate original purchase price of $1,000,000 (as adjusted
for stock splits, stock dividends, combinations and other recapitalizations).
For purposes of calculating holdings under this Section 2.3, an Investor's
holdings shall include Shares held by any general partners and affiliates or
entities under common investment management of such Investor. An Investor

                                       15

<PAGE>

shall be entitled to apportion the right of first offer hereby granted it among
itself and its partners and affiliates or entities under common investment
management in such proportions as it deems appropriate.

                  Each time the Company proposes to offer any shares of, or
securities convertible into or exchangeable or exercisable for any shares of,
any class of its capital stock (the "SHARES"), the Company shall first make an
offering of such Shares to each Major Investor in accordance with the following
provisions.

                           (a)      The Company shall deliver a notice in
accordance with Section 4.5 (the "NOTICE") to the Major Investors stating (i)
its bona fide intention to offer such Shares, (ii) the number of such Shares to
be offered, and (iii) the price and terms upon which it proposes to offer such
Shares.

                           (b)      By written notification received by the
Company, within twenty (20) calendar days after receipt of the Notice, the Major
Investor may elect to purchase or obtain, at the price and on the terms
specified in the Notice, up to that portion of such Shares that equals the
proportion that the number of shares of Common Stock issued and held, or
issuable upon conversion of the Preferred Stock or upon exercise of warrants to
purchase Preferred Stock then held, by such Major Investor bears to the total
number of shares of Common Stock of the Company then outstanding (assuming full
conversion of all outstanding convertible securities and full exercise of all
outstanding options, warrants and all other exercisable securities). The Company
shall promptly, in writing, inform each Major Investor that elects to purchase
all the shares available to it (a "FULLY-EXERCISING INVESTOR") of any other
Major Investor's failure to do likewise. During the ten (10) day period
commencing after such information is given, each Fully-Exercising Investor may
elect to purchase that portion of the Shares for which Major Investors were
entitled to subscribe but which were not subscribed for by the Major Investors
that is equal to the proportion that the number of shares of Common Stock issued
and held, or issuable upon conversion of the Preferred Stock or upon exercise of
warrants to purchase Preferred Stock then held, by such Fully-Exercising
Investor bears to the total number of shares of Common Stock issued or and held,
or issuable upon conversion of the Preferred Stock or upon exercise of warrants
to purchase Preferred Stock then held, by all Fully-Exercising Investors who
wish to purchase some of the unsubscribed shares.

                           (c)      If all Shares that Investors are entitled to
purchase pursuant to subsection 2.3(b) are not elected to be purchased as
provided in subsection 2.3(b) hereof, the Company may, during the ninety (90)
day period following the expiration of the period provided in subsection 2.3(b)
hereof, offer the remaining unsubscribed portion of such Shares to any person or
persons at a price not less than, and upon terms no more favorable to the
offeree than those specified in the Notice. If the Company does not enter into
an agreement for the sale of the Shares within such period, or if such agreement
is not consummated within thirty (30) days of the execution thereof, the right
provided hereunder shall be deemed to be revived and such Shares shall not be
offered unless first reoffered to the Major Investors in accordance herewith.

                           (d)      The right of first offer in this Section 2.3
shall not be applicable to (i) the issuance or sale of shares of Common Stock
(or options therefor) to employees, consultants or directors (if in transactions
with primarily non-financing purposes) of

                                       16

<PAGE>

the Company directly or pursuant to a stock plan or restricted stock plan
approved by the Board of Directors of the Company; (ii) the issuance of
securities pursuant to a bona fide, firmly underwritten public offering of
shares of Common Stock, registered under the Act, at an offering price of at
least $12.00 per share (appropriately adjusted for any stock split, dividend,
combination or other recapitalization) and resulting in proceeds to the Company
of at least $40,000,000 in the aggregate, (iii) the issuance of securities
pursuant to the conversion or exercise of convertible or exercisable securities,
(iv) the issuance of securities in connection with a bona fide business
acquisition of or by the Company, whether by merger, consolidation, sale of
assets, sale or exchange of stock or otherwise, that is approved by the Board of
Directors of the Company, (v) the issuance of stock, warrants or other
securities or rights to persons or entities with which the Company has strategic
business relationships, pursuant to agreements outstanding as of the date hereof
or subsequently approved by the Board of Directors of the Company and, from the
date hereof, do not exceed in the aggregate seven percent (7%) of the
outstanding capital stock of the Company at any time or (vi) the issuance of
stock, warrants or other securities issued to equipment lessors, a bank or
similar financial institution from which a credit line or bank loan is provided
to the Company, or real estate lessors, provided that such issuances are for
other than primarily equity financing purposes and are approved by the Board of
Directors of the Company and, from the date hereof, do not exceed in the
aggregate two percent (2%) of the outstanding capital stock of the Company at
any time.

                           (e)      Notwithstanding anything in this Agreement
to the contrary, if the New Investor qualifies as a Major Investor at the time
the Company proposes to offer Shares under this Section 2.3, in no event shall
the New Investor have the right to acquire any Shares hereunder to the extent
that the aggregate number of shares of capital stock of the Company held by New
Investor and its affiliates, directly or indirectly, following such acquisition
would exceed ten percent (10%) of the total outstanding shares of Common Stock,
determined on a fully-diluted basis (i.e., assuming the conversion into shares
of Common Stock of all outstanding shares of Preferred Stock and other
convertible securities of the Company and the exercise of all options, warrants
and other rights to purchase shares of capital stock of the Company which are
outstanding under any stock option or other stock incentive plans approved by
the Board of Directors).

                  2.4      Stock Plan. From the date hereof until July 23, 2003,
the Company shall not issue options for the purchase of Common Stock in excess
of 4,976,563 shares.

                  2.5      Compensation Committee. The Compensation Committee
shall be comprised of three (3) members of the Board of Directors; provided,
that, one (1) member of such Compensation Committee shall be selected by
majority vote of the directors elected by the holders of Common Stock and Series
A Preferred Stock and at least two (2) members of such Compensation Committee
shall be selected by majority vote of the director elected by the holders of
Series B Preferred Stock (the "SERIES B DIRECTOR") and the directors elected by
the holders of Series C Preferred Stock (the "SERIES C DIRECTORS"), which
initially shall be one of the Series C Directors designated by J.P. Morgan
Partners (BHCA), L.P. ("J.P. MORGAN") and one director selected by the Series B
Director and Series C Directors that is not a J. P Morgan representative.

                                       17

<PAGE>

                  2.6      Preservation of Corporate Existence. The Company
shall preserve and maintain its corporate existence, rights, franchises and
privileges in the jurisdiction of its incorporation, and qualify and remain
qualified, and cause each subsidiary to qualify and remain qualified, as a
foreign corporation in each jurisdiction in which such qualification is
necessary or desirable in view of its business and operations or the ownership
or lease of its properties; provided, however, that nothing in this Section 2.6
shall be deemed to preclude any merger, consolidation, liquidation or sale
(subject to it not being a sale of substantially all of the assets of the
Company and its subsidiaries, taken as a whole) of any subsidiary if such action
is approved by the Board of Directors of the Company as being in the best
interest of the Company.

                  2.7      Intellectual Property. The Company shall preserve and
maintain all licenses and other rights to use patents, processes, licenses,
permits, trademarks, trade names, inventions, intellectual property rights or
copyrights owned or possessed by it and deemed by the Company to be necessary to
the conduct of its business or the business of its subsidiaries taken as a
whole.

                  2.8      Compliance with Laws. The Company shall comply with
the requirements of all applicable laws, rules, regulations and orders of any
governmental authority, noncompliance with which could materially adversely
affect the business or condition, financial or otherwise, of the Company and its
subsidiaries, taken as a whole.

                  2.9      Payment of Taxes. The Company shall deposit all taxes
due to any governmental unit with respect to compensation paid to any employee
of the Company on or before the due date therefor. The Company agrees to pay or
cause to be paid all taxes, assessments and other governmental charges levied
upon any of its properties or assets, or in respect of its franchises,
businesses, income or profits before the same become delinquent, except that
(unless and until foreclosure, sale or other similar proceedings shall have been
commenced) no such charge need be paid if being contested in good faith and by
appropriate proceedings promptly initiated and diligently conducted, and if
appropriate reserves have been established therefor on the books of the Company
to the extent required by GAAP.

                  2.10     Preservation of Property. The Company shall preserve,
protect and maintain all of its properties necessary or useful in the proper
conduct of its business in good working order and condition, with the exception
of (i) ordinary wear and tear and (ii) casualty losses covered by insurance,
allowing for reasonable deductibles; provided that the Company shall not be
required to do so with respect to any property if Board of Directors shall
determine that the preservation of such property is no longer desirable in the
conduct of the business of the Company as a whole.

                  2.11     Reservation of Shares. The Company shall at all times
reserve and keep available, solely for issuance and delivery upon the conversion
of the Preferred Stock and exercise of all outstanding warrants, all Common
Stock, Series B Preferred Stock, Series C-1 Preferred Stock and Series C-2
Preferred Stock issuable from time to time upon such conversion or exercise.

                                       18

<PAGE>

                  2.12     Special Board Votes. (i) The following actions shall
not be taken by the Company unless it has obtained the affirmative approval and
vote of at least 66 2/3% of the entire Board of Directors:

                           (A)      any acquisition by the Company of any other
company or entity pursuant to acquisition of stock or of all or substantially
all of the assets of such other company or entity, when the aggregate
consideration paid is in excess of $10,000,000 (and, in cases where such
consideration does not consist of cash or marketable securities, the value shall
be as determined in good faith by a majority of the Board of Directors); and

                           (B)      any transaction between the Company and any
employee at the director or more senior level (a "SENIOR EMPLOYEE"), officer or
director of the Company, or any affiliate thereof, other than (1) offers or
agreements of employment, including all terms associated therewith, (2) all
compensation related matters, (3) stock option grants to Senior Employees,
officers or directors (including loans for the exercise of options), (4)
advances for travel, entertainment and other such matters in the ordinary course
of business, (5) loans to, or loan guarantees for the benefit of, any person who
is a Senior Employee, officer or director of the Company not in excess of
$100,000, and (6) loans made in connection with the initial employment offer to,
or loan guarantees made in connection with the initial employment offer for the
benefit of, any Senior Employee, officer or director of the Company hired after
the date hereof.

                  (ii)     The affirmative approval of a majority of the entire
Board of Directors shall be required to approve the Company's annual budget.

                  2.13     Termination of Covenants. The covenants set forth in
this Section 2 shall terminate as to the Investors and be of no further force or
effect upon the closing of a firm commitment underwritten public offering
pursuant to an effective registration statement under the Act or when the
Company first becomes subject to the periodic reporting requirements of Sections
12(g) or 15(d) of the 1934 Act, whichever event shall first occur; provided that
any party's liability for breaches of this Agreement shall survive for a period
of 90 days following any such termination.

         3.       Covenants of the Investors.

                  3.1      Confidentiality. Except as may be required by any law
or regulation or as otherwise agreed in writing by the Company, each Investor
agrees that it will maintain the confidentiality of any proprietary information
of the Company obtained by it, pursuant to this Agreement or by virtue of its
relationship as a stockholder of the Company, which is not otherwise lawfully
available from other sources, subject to the disclosure of information as
required by law or the order of any court or governmental authority or upon
request or requirement of any governmental agency having regulatory authority
over such Investor or any rating agency or the disclosure of information of a
non-technical nature, including summary financial information, which such
Investor may disclose to its partners and/or stockholders.

                                       19

<PAGE>

                  3.2      Public Announcements. Each Investor hereby agrees
that, except as otherwise required by law or regulation (including without
limitations, the regulations of any stock exchange on which the Investor's
securities are then listed), neither it nor any of its affiliates will (a)
except as may otherwise have been agreed in writing by the Company, issue any
press release or public announcement with respect to the sale of Series D
Preferred Stock or the transactions contemplated by the Series D Agreement (the
"SERIES D TRANSACTIONS") without the prior written consent of the Company and
the New Investor or (b) issue any public announcement or press release that
includes the name of any other Investor (the "NAMED INVESTOR") without the prior
written consent to such use by the Named Investor, which consent under clause
(a) above shall not be unreasonably delayed or withheld; provided, however, (i)
nothing in the foregoing shall prevent an Investor from disclosing the existence
and general terms of its investment in the Company to its shareholders,
affiliates, limited partners, and entities under common control so long as such
disclosures are made subject to clause (b) above only with respect to a Named
Investor; and provided, further, that (ii) after such time as either the Company
or the New Investor issues a press release with respect to the Series D
Transactions, each Investor will be relieved of its obligation to seek the
consent of the Company and the New Investor under clause (a) above but will
still be required to comply with clause (b) but only with respect to Named
Investors. Subject to the foregoing, each Investor shall provide the Company and
the New Investor with a copy of any press release or public announcement it
makes with respect to the Series D Transactions at the time it issues such
release or announcement.

         4.       Miscellaneous.

                  4.1      Successors and Assigns. Except as otherwise provided
herein, the terms and conditions of this Agreement shall inure to the benefit of
and be binding upon the respective successors and assigns of the parties
(including transferees of any shares of Registrable Securities). Nothing in this
Agreement, express or implied, is intended to confer upon any party other than
the parties hereto or their respective successors and assigns any rights,
remedies, obligations, or liabilities under or by reason of this Agreement,
except as expressly provided in this Agreement.

                  4.2      Governing Law. This Agreement shall be governed by
and construed under the laws of the State of New York as applied to agreements
among New York residents entered into and to be performed entirely within New
York.

                  4.3      Counterparts. This Agreement may be executed in two
or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument.

                  4.4      Titles and Subtitles. The titles and subtitles used
in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.

                  4.5      Notices. Unless otherwise provided, any notice
required or permitted under this Agreement shall be given in writing and shall
be deemed effectively given upon personal delivery to the party to be notified
or upon delivery by confirmed facsimile

                                       20

<PAGE>

transmission, nationally recognized overnight courier service, or three (3)
business days after deposit with the United States Post Office, by registered or
certified mail, postage prepaid and addressed to the party to be notified at the
address indicated for such party on the signature page hereof, or at such other
address as such party may designate by ten (10) days' advance written notice to
the other parties.

                  4.6      Expenses. If any action at law or in equity is
necessary to enforce or interpret the terms of this Agreement, the prevailing
party shall be entitled to reasonable attorneys' fees, costs and necessary
disbursements in addition to any other relief to which such party may be
entitled.

                  4.7      Entire Agreement: Amendments and Waivers. This
Agreement (including the Exhibits hereto, if any) constitutes the full and
entire understanding and agreement among the parties with regard to the subject
matter hereof and thereof. Any term of this Agreement may be amended and the
observance of any term of this Agreement may be waived (either generally or in a
particular instance and either retroactively or prospectively), only with the
written consent of the Company and the holders of at least 66-2/3% of the
Registrable Securities; provided, however, that (a) the right of the directors
appointed by the holders of Common Stock and Series A Preferred Stock to
designate a member to the Compensation Committee of the Board of Directors
pursuant to Section 2.5(a) hereof may not be amended without the written consent
of at least 66-2/3% of the Registrable Securities held by David Guyer, Martin
Glick, John McLaughlin and Samir Patel and (b) the right of the directors
appointed by the holders of Series B Preferred Stock and Series C Preferred
Stock to designate two (2) members to the Compensation Committee of the Board of
Directors pursuant to Section 2.5(a) hereof may not be amended without the
written consent of at least 66-2/3% of the Series B Preferred Stock and Series C
Preferred Stock (voting together as a single class); provided, further, that in
the event any amendment or waiver hereof treats any Holder in a manner different
from any other Holder, such amendment or waiver shall also require the written
consent of the Holder so affected. Any amendment or waiver effected in
accordance with this Section shall be binding upon each holder of any
Registrable Securities, each future holder of all such Registrable Securities,
and the Company. Notwithstanding the foregoing, the provisions of Section 1.12
hereof may not be amended without the written consent of the New Investor.

                  4.8      Severability. If one or more provisions of this
Agreement are held to be unenforceable under applicable law, such provision
shall be excluded from this Agreement and the balance of the Agreement shall be
interpreted as if such provision was so excluded and shall be enforceable in
accordance with its terms.

                  4.9      Aggregation of Stock. All shares of Registrable
Securities held or acquired by affiliated entities or persons, or entities under
common investment management, shall be aggregated together for the purpose of
determining the availability of any rights under this Agreement.

                  4.10     Termination of Prior Agreement. The Prior Agreement
is hereby terminated and superseded in its entirety by this Agreement. Each
party to this Agreement hereby waives under the Prior Agreement its right to
notice of, and to purchase, its "PRO RATA SHARE" of the "SECURITIES" issued or
issuable pursuant to the Series D Agreement, including the

                                       21

<PAGE>

NDA Shares and the Post-IPO Shares (as defined therein). To the knowledge of the
Company, no party to the Prior Agreement was in default thereunder immediately
prior to the termination thereof pursuant to this Section.

                          [Signature Pages to Follow.]

                                       22

<PAGE>

                  IN WITNESS WHEREOF, the parties have executed this Agreement
as of the date first above written.

                                        EYETECH PHARMACEUTICALS, INC.

                                        By: /s/ DAVID R. GUYER
                                            ------------------------------------
                                            Name: David R. Guyer
                                            Title: CEO

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first written above.

                                        PFIZER IRELAND PHARMACEUTICALS

                                        By: /s/ CIARAN KEANEY
                                            ---------------------------------
                                            Name: Ciaran Keaney
                                            Title: Company Secretary

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                        J.P. MORGAN PARTNERS (BHCA), L.P.

                                        By: JPMP MASTER FUND MANAGER, L.P.,
                                            ITS GENERAL PARTNER

                                        By: JPMP CAPITAL CORP.,
                                            ITS GENERAL PARTNER

                                        By:    /s/ DAMION E. WICKER, M.D.
                                            ------------------------------------
                                            Name: Damion E. Wicker, M.D.
                                            Title: Partner

                               Address: 1221 Avenue of the Americas, 39th Floor
                                        New York, NY 10020-1080
                                        Attention: Official Notices Clerk
                                        (fbo Srinivas Akkaraju)

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

               Executed as of the date first above written.

                                  ALTA BIOPHARMA PARTNERS II, L.P.

                                  By: Alta BioPharma Management Partners II, LLC
                                      Its General Partner

                                  By: /s/ [ILLEGIBLE]
                                      -----------------------------------------
                                      Director

                                  ALTA EMBARCADERO BIOPHARMA PARTNERS II, LLC

                                  By: /s/ HILARY STRAIN
                                      ----------------------------------
                                      V.P. of Finance & Admin.

                         Address: One Embarcadero Center, Suite 4050
                                  San Francisco, CA 94111

              SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
             AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                  16-Dec-2002          BIOTECH GROWTH N.V.

                                       By:  /s/ ANDERS HOVE
                                            ------------------------------------
                                            Title: Signatory Authority

                                       By:  /s/ A. HOVE
                                            ------------------------------------
                                            Title: Signatory Authority

                              Address: Bellevue Asset Management
                                       Grafenauweg 4
                                       Postfach 6201
                                       Zug
                                       Switzerland
                                       Attention: Anders Hove

                              Address: Bellevue Research
                                       111 Huntington Avenue
                                       Suite 510
                                       Boston, MA 02199-7610
                                       Attention: Michael Mullen

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                             MPM BIOVENTURES II, L.P.

                             By: MPM Asset Management II, L.P.,
                                 its General Partner

                             By: MPM Asset Management II LLC,
                                 its General Partner

                             By:  /s/ KURT C. WHEELER
                                  ---------------------------------------
                                  Name: Kurt C. Wheeler
                                  Title: Investment Manager

                             MPM BIOVENTURES II-QP, L.P.

                             By: MPM Asset Management II, L.P.,
                                 its General Partner

                             By: MPM Asset Management II LLC,
                                 its General Partner

                             By: /s/ KURT C. WHEELER
                                 ---------------------------------------
                                 Name: Kurt C. Wheeler
                                 Title: Investment Manager

                             MPM BIOVENTURES GMBH & CO.
                             PARALLEL-BETEILIGUNGS KG

                             By: MPM Asset Management II, L.P.,
                                 in its capacity as the Special Limited Partner

                             By: MPM Asset Management II LLC,
                                 its General Partner

                             By: /s/ KURT C. WHEELER
                                 ---------------------------------------
                                 Name: Kurt C. Wheeler
                                 Title: Investment Manager

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                MPM ASSET MANAGEMENT INVESTORS 2001 LLC

                                By: /s/ KURT C. WHEELER
                                    ---------------------------------------
                                    Name: Kurt C. Wheeler
                                    Title: Investment Manager

                       Address: 601 Gateway Blvd., # 350
                                San Francisco, CA 94080

                                MPM BIOEQUITIES MASTER FUND LP

                                By: MPM BioEquities Advisor LLC

                                By: /s/ KURT VON EMSTER
                                   ---------------------------------------
                                   Name: Kurt von Emster
                                   Title: Managing Member

                       Address: 601 Gateway Blvd., # 350
                                San Francisco, CA 94080

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                              SCHRODER VENTURES INTERNATIONAL LIFE SCIENCES
                              FUND II LP1

                              By: Schroder Venture Managers Inc. as
                                  General Partner

                              By: /s/ NICOLA WALKER          /s/ GARY CARR
                                  ----------------------------------------------
                                  Name: N. Walker            G. Carr
                                  Title: Director & Vice President

                              SCHRODER VENTURES INTERNATIONAL
                              LIFE SCIENCES FUND II LP2

                              By: Schroder Venture Managers Inc. as
                                  General Partner

                              By: /s/ NICOLA WALKER          /s/ GARY CARR
                                  ----------------------------------------------
                                  Name: N. Walker            G. Carr
                                  Title: Director & Vice President

                              SCHRODER VENTURES INTERNATIONAL
                              LIFE SCIENCES FUND II LP3

                              By: Schroder Venture Managers Inc. as
                                  General Partner

                              By: /s/ NICOLA WALKER          /s/ GARY CARR
                                  ----------------------------------------------
                                  Name: N. Walker            G. Carr
                                  Title: Director & Vice President

                              SCHRODER VENTURES INVESTMENTS LIMITED

                              By: SV (Nominees) Limited as Nominee of

                              By:  _____________________________________________
                                   Name:
                                   Title:

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                               SCHRODER VENTURES INTERNATIONAL LIFE SCIENCES
                               FUND II GROUP CO-INVESTMENT SCHEME

                               By: SITCO Nominees Ltd. - VC 01903 as
                                    Nominee of

                               By: /s/ NICOLA WALKER, /s/ GARY CARR
                                   ---------------------------------------------
                                   Name: N. Walker, G. Carr
                                   Title: Directors

                               SCHRODER VENTURES INTERNATIONAL LIFE SCIENCES
                               FUND II STRATEGIC PARTNERS L.P.

                               By: Schroder Venture Managers Inc. as
                                   General Partner

                               By: /s/ NICOLA WALKER, /s/ GARY CARR
                                   ---------------------------------------------
                                   Name: N. Walker, G. Carr
                                   Title: Director & Vice President

                      Address: c/o 22 Church Street
                               Hamilton HM11 Bermuda

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                                   INTERNATIONAL BIOTECHNOLOGY TRUST PLC.

                                   By: International Biotechnology Trust plc.

                                   By: /s/ KATE BINGHAM
                                       -----------------------------------------
                                       Name: Kate Bingham
                                       Title: Signatory

                          Address: International Biotechnology Trust plc.
                                   71 Kingsway
                                   London, UK
                                   WC, 2B 6ST

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                LAKEVIEW EYETECH, L.P.

                                By:  /s/ THOMAS ELDEN
                                     --------------------------------
                                     Name: Thomas Elden
                                     Title: Managing Member/G.P.

                                LAKEVIEW EYETECH II, L.P.

                                By: Private Capital Investors, LLC
                                    Its General Partner

                                By: /s/ THOMAS ELDEN
                                    --------------------------------
                                    Name: Thomas Elden
                                    Title: Managing Member

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                   For Entities:

                                   Teachers Insurance and Annuity
                                   Association of America
                                   [Print Name of Entity]

                                   By: /s/ HOLLY HOLTZ                SAS
                                       ----------------------------------
                                       [Signature]

                                       Holly Holtz
                                       ----------------------------------
                                       [Print Name]

                                       Director
                                       [Print Title

                          Address: 730 Third Avenue
                                   New York, New York 10017

                                   For Individuals

                                   ______________________________________
                                   [Signature]

                                   ______________________________________
                                   [Print Name]

                          Address: ______________________________________
                                   ______________________________________

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                  GILEAD SCIENCES, INC.

                                  By: /s/ JOHN F. MILLIGAN
                                      -----------------------------
                                      Name: John Milligan
                                      Title: Sr. VP and CFO

                         Address: 333 Lakeside Drive
                                  Foster City, CA 94404

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                   For Entities:

                                   _____________________________________________
                                   [Print Name of Entity]

                                   By: _________________________________________
                                       [Signature]

                                       _________________________________________
                                       [Print Name]

                                       _________________________________________
                                       [Print Title

                          Address: _____________________________________________
                                   _____________________________________________

                                   For Individuals

                                   /s/ ALAN J. BILOSKI
                                   ---------------------------------------------
                                   [Signature]

                                   Alan J. Biloski
                                   ---------------------------------------------
                                   [Print Name]

                          Address: _____________________________________________
                                   _____________________________________________

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                       /s/ NEETA DEMEULENAERE
                                       -----------------------------------------
                                       Neeta Demeulenaere

                                       /s/ GILES DEMEULENAERE
                                       -----------------------------------------
                                       Giles Demeulenaere

                              Address: 100 E. Bellevue Pl. # 8D
                                       Chicago, IL 60611

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                   For Entities:

                                   Feldman Family Revocable Living
                                   Trust as amended & restated in 2000
                                   [Print Name of Entity]

                                   By: /s/ ROBERT C. FELDMAN
                                       -----------------------------------------
                                       [Signature]

                                       Robert C. Feldman
                                       -----------------------------------------
                                       [Print Name]

                                       Trustee
                                       [Print Title

                          Address: 868 Parliament Road
                                   Oakland, CA 94610-2437

                                   For Individuals

                                   _____________________________________________
                                   [Signature]

                                   _____________________________________________
                                   [Print Name]

                          Address: _____________________________________________
                                   _____________________________________________

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                       For Entities:

                                       G&H Partners
                                       [Print Name of Entity]

                                       By: /s/ JONATHAN GLEASON
                                           -------------------------------------
                                           [Signature]

                                           Jonathan Gleason
                                           -------------------------------------
                                           [Print Name]

                                           _____________________________________
                                           [Print Title

                              Address: _________________________________________
                                       _________________________________________

                                       For Individuals

                                       _________________________________________
                                       [Signature]

                                       _________________________________________
                                       [Print Name]

                              Address: _________________________________________
                                       _________________________________________

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                     For Entities:

                                     ___________________________________________
                                     [Print Name of Entity]

                                     By: _______________________________________
                                         [Signature]

                                         _______________________________________
                                         [Print Name]

                                         _______________________________________
                                         [Print Title

                            Address: ___________________________________________
                                     ___________________________________________

                                     For Individuals

                                     /s/ HOWARD M. GARDNER
                                     -------------------------------------------
                                     [Signature]

                                     Howard M. Gardner
                                     -------------------------------------------
                                     [Print Name]

                            Address: 10 Royal Crest Drive, Apt. 9
                                     North Andover, MA 01845

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                       For Entities:

                                       _________________________________________
                                       [Print Name of Entity]

                                       By: _____________________________________
                                           [Signature]

                                           _____________________________________
                                           [Print Name]

                                           _____________________________________
                                           [Print Title

                              Address: _________________________________________
                                       _________________________________________

                                       For Individuals

                                       /s/ CLIFTON L. GRAY
                                       -----------------------------------------
                                       [Signature]

                                       Clifton L. Gray
                                       -----------------------------------------
                                       [Print Name]

                              Address: _________________________________________
                                       _________________________________________

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                       For Entities:

                                       ________________________________________
                                       [Print Name of Entity]

                                       By: ____________________________________
                                           [Signature]

                                           ____________________________________
                                           [Print Name]

                                           ____________________________________
                                           [Print Title

                              Address: ________________________________________
                                       ________________________________________

                                       For Individuals

                                       /s/ ROBERT D. GRAY, JR.
                                       ----------------------------------------
                                       [Signature]

                                       Robert D. Gray, Jr.
                                       ----------------------------------------
                                       [Print Name]

                              Address: ________________________________________
                                       ________________________________________

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                           For Entities:

                                           _____________________________________
                                           [Print Name of Entity]

                                           By: _________________________________
                                               [Signature]

                                               _________________________________
                                               [Print Name]

                                               _________________________________
                                               [Print Title

                                  Address: _____________________________________
                                           _____________________________________

                                           For Individuals

                                           /s/ MARION GRILLO
                                           -------------------------------------
                                           [Signature]

                                           Marion Grillo
                                           -------------------------------------
                                           [Print Name]

                                  Address: 16 Bramley Hill Road, PO Box 734
                                           Windham, NH 03087

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                   For Entities:

                                                                     UTD 5/21/98

                                   Thomas E. Hayes Trust
                                   [Print Name of Entity]

                                   By: /s/ THOMAS E. HAYES
                                       -----------------------------------------
                                       [Signature]

                                       Thomas E. Hayes
                                       -----------------------------------------
                                       [Print Name]

                                       Trustee
                                       [Print Title

                          Address: _____________________________________________
                                   _____________________________________________

                                   For Individuals

                                   _____________________________________________
                                   [Signature]

                                   _____________________________________________
                                   [Print Name]

                          Address: _____________________________________________
                                   _____________________________________________

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                  For Entities:

                                                                  U/A DTD 1/6/98
                                  Kleinman Revocable Trust
                                  [Print Name of Entity]

                                  By: /s/ LARRY M. KLEINMAN
                                      ------------------------------------------
                                      [Signature]

                                      Larry M. Kleinman
                                      ------------------------------------------
                                      [Print Name]

                                      Trustee
                                      [Print Title

                                  PO Box 370795
                         Address: 900 Hawthorne St
                                  Montana CA 94037

                                  For Individuals

                                  ______________________________________________
                                  [Signature]

                                  ______________________________________________
                                  [Print Name]

                         Address: ______________________________________________
                                  ______________________________________________

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                       For Entities:

                                       _________________________________________
                                       [Print Name of Entity]

                                       By: _____________________________________
                                           [Signature]

                                           _____________________________________
                                           [Print Name]

                                           _____________________________________
                                           [Print Title

                              Address: _________________________________________
                                       _________________________________________

                                       For Individuals

                                       /s/ DAVID D. LARDNER
                                       -----------------------------------------
                                       [Signature]

                                       David D. Lardner
                                       -----------------------------------------
                                       [Print Name]

                              Address: 42 Remington Ct
                                       Danville, CA 94526

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                       For Entities:

                                       Minchello Partnership
                                       [Print Name of Entity]

                                       By: /s/ ROBERT V. MINCHELLO
                                           -------------------------------------
                                           [Signature]

                                           Robert V. Minchello
                                           -------------------------------------
                                           [Print Name]

                                           General Partner
                                           [Print Title

                              Address: _________________________________________
                                       _________________________________________

                                       For Individuals

                                       _________________________________________
                                       [Signature]

                                       _________________________________________
                                       [Print Name]

                              Address: _________________________________________
                                       _________________________________________

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                       For Entities:

                                       Minchello Partnership
                                       [Print Name of Entity]

                                       By: /s/ JAMES MINCHELLO
                                           -------------------------------------
                                           [Signature]

                                           James Minchello
                                           -------------------------------------
                                           [Print Name]

                                           President
                                           [Print Title

                              Address: 29 Amberwood Drive
                                       Winchester, MA 01890

                                       For Individuals

                                       _________________________________________
                                       [Signature]

                                       _________________________________________
                                       [Print Name]

                              Address: _________________________________________
                                       _________________________________________

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                       For Entities:

                                       _________________________________________
                                       [Print Name of Entity]

                                       By: _____________________________________
                                           [Signature]

                                           _____________________________________
                                           [Print Name]

                                           _____________________________________
                                           [Print Title

                              Address: _________________________________________
                                       _________________________________________

                                       For Individuals

                                       /s/ CHANDRAKANT M. PATEL
                                       -----------------------------------------
                                       [Signature]

                                       Chandrakant M. Patel
                                       -----------------------------------------
                                       [Print Name]

                              Address: 13 Kathleen Drive
                                       Andover, MA 01810

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                       /s/ NARENDRA PATEL
                                       -----------------------------------------
                                       Narendra Patel

                                       /s/ ILAKUMARI PATEL
                                       -----------------------------------------
                                       Ilakumari Patel

                              Address: 29 Dublin Drive
                                       Niskayuna, NY 12309

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                           /s/ NAVIN PATEL
                                           -------------------------------------
                                           Navin Patel

                                  Address: 29 Dublin Drive
                                           Niskayuna, NY 12309

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                          /s/ NEIL PATEL
                                          -------------------------------------
                                          Neil Patel

                                 Address: 1320 30th St. NW
                                          Washington, DC 20007

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                           /s/ NISHA PATEL
                                           -------------------------------------
                                           Nisha Patel

                                 Address:  122 Saint Botolph
                                           Unit 3
                                           Boston, MA 02115

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                           /s/ SYRYAKANT M. PATEL, M.D.
                                           ------------------------------------
                                           Syryakant M. Patel, M.D.

                                  Address: 11 Bay View Road
                                           P.O. Box 817
                                           Webster, MA 01570

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                          For Entities:

                                          ______________________________________
                                          [Print Name of Entity]

                                          By: __________________________________
                                              [Signature]

                                              __________________________________
                                              [Print Name]

                                              __________________________________
                                              [Print Title

                                 Address: ______________________________________
                                          ______________________________________

                                          For Individuals

                                          /s/ ARTHUR J. REMILLARD, JR.
                                          --------------------------------------
                                          [Signature]

                                          Arthur J. Remillard, Jr.
                                          --------------------------------------
                                          [Print Name]

                                 Address: 211 Main Street
                                          Webster, MA 01570

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                           For Entities:

                                           Bradford J. Shafer Revocable
                                           Inter Vivos Trust Dated 10-30-97
                                           [Print Name of Entity]

                                           By: /s/ BRAD SHAFER
                                               ---------------------------------
                                               [Signature]

                                               Brad Shafer
                                               ---------------------------------
                                               [Print Name]

                                               Trustee
                                               [Print Title

                                  Address: 626 16th Ave.
                                           SF CA 94118

                                           For Individuals

                                           _____________________________________
                                           [Signature]

                                           _____________________________________
                                           [Print Name]

                                  Address: _____________________________________
                                           _____________________________________

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                          For Entities:

                                          ______________________________________
                                          [Print Name of Entity]

                                          By: __________________________________
                                              [Signature]

                                              __________________________________
                                              [Print Name]

                                              __________________________________
                                              [Print Title

                                 Address: ______________________________________
                                          ______________________________________

                                          For Individuals

                                          /s/ GURBACHAN SINGH
                                          --------------------------------------
                                          [Signature]

                                          Gurbachan Singh
                                          --------------------------------------
                                          [Print Name]

                                 Address: 102 Union Point
                                          Webster, MA 01570

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                  Executed as of the date first above written.

                                             /s/ RONALD S. WEISS, M.D.
                                             -----------------------------------
                                             Ronald S. Weiss, M.D.

                                    Address: 2659 N. Magnolia Avenue
                                             Chicago, IL 60614

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT

<PAGE>

                   Executed as of the date first above written.

                                       For Entities:

                                       _________________________________________
                                       [Print Name of Entity]

                                       By: _____________________________________
                                           [Signature]

                                           _____________________________________
                                           [Print Name]

                                           _____________________________________
                                           [Print Title

                              Address: _________________________________________
                                       _________________________________________

                                       For Individuals

                                       _________________________________________
                                       [Signature]

                                       _________________________________________
                                       [Print Name]

                              Address: _________________________________________
                                       _________________________________________

                 SIGNATURE PAGE TO EYETECH PHARMACEUTICALS, INC.
                AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT
<PAGE>

                                   SCHEDULE A

                                    INVESTORS

David Guyer
John McLaughlin
Martin Glick
Samir Patel
Ashok and Nila Shah
Vina Patel
Minchello Partnership
Nisha Patel
Neelu Sharma
Floyd Yuen
Clifton L. Gray
Neil Patel
Herman F. Becker
Gerbachan B. Singh
Naren and Ilakumari Patel
Robert L. and JoAnn M. Puchalski
Tucker Carlson
Arthur J. Remillard, Jr.
Stephen R. Du Bois
Suryakant M. Patel
Mahendra G. Shah
Ronald S. Weiss
Robert D. Gray
Richard Y. and Jania N. Woo
Paul J. Santo
Neeta and Giles Demeulenaere
Marion Grillo
Chandrakant M. Patel
Douglas E. and Carol B. Cohen
Cohen 1999 Dynastic Trust
Michael and Jill Cohen Dynastic Trust
Scott and Jennifer Cohen Dynastic Trust
Richard A. Pierro, Jr.
Andover Angels III, LLC
Navin B. Patel
Harry Koster
Robert H. Bergman
Kerry K. Assil
Howard M. Gardner
John Montgomery
Alan J. Biloski
Philip Shwon
Ernest Kornmehl

                                      S-1

<PAGE>

                               SCHEDULE A (CONT'D)

                                    INVESTORS

Larry and Carol Klienman Revocable Trust
The Nielsen Family Trust
David Lessen
Thomas E. Hayes Trust
David D. Lardner
Michael A. Wilson
Lakeview Eyetech, L.P.
Lakeview Eyetech II, L.P.
Merrill Lynch Kecalp L.P. 1999
Kecalp Inc., as nominee for Merrill Lynch Kecalp International L.P. 1999
Merrill Lynch Ventures L.P. 2001
J.P. Morgan Partners (BHCA), L.P.
Alta BioPharma Partners II, L.P.
Alta Embarcadero BioPharma Partners II, LLC
Teachers Insurance and Annuity Association of America
Ontario Teacher's Pension Plan
Lotus BioScience Investment Holdings Limited
Biotech Growth S.A.
MPM BioVentures II, LP
MPM Bioventures II-QP, LP
MPM BioVentures GmbH & Co. Parallel-Beteiligungs KG
MPM Asset Management Investors 2001 LLC
MPM BioEquities Master Fund, LP
Amerindo Internet Fund PLC
Amerindo Master Venture Fund LLC
Amerindo Technology Growth Fund II Inc.
Mitchell P. Bartlett
Selena Chaisson
Daniel Chapey
William F. Hartfiel, III
K. Flynn McDonald
James Stableford
JaDeane Ing
Schroder Ventures International Life Science Fund II LP1
Schroder Ventures International Life Science Fund II LP2
Schroder Ventures International Life Science Fund II LP3
Schroder Ventures Investments Limited
Schroder Ventures International Life Science Fund II Group Co-Investment Scheme
Schroder Ventures International Life Science Fund II Strategic Partners L.P.
International Biotechnology Trust plc.

                                      S-2

<PAGE>

                               SCHEDULE A (CONT'D)

                                    INVESTORS

Novartis BioVentures Ltd.
Prescient Partners I, L.L.C.
Robert A. & Rosemary G. Baffi, as Trustees for the Baffi Family Revocable Trust
Anders D. Hove
Charles Schwab & Co., Inc. FBO Nirmala M. Ray Keogh
G&H Partners
Lorne M. Buchman
Robert C. Feldman & Flora Ann Peters Feldman, as Trustees of the Feldman Family
   Revocable Living Trust as amended and restated in 2000
Neal Glick as Custodian for Charlotte R. Glick and Matthew N. Glick
Argeris N. Karabelas
Joseph M. Maurer
John R. Reimann
Bradford J. Shafer Revocable Inter Vivos Trust dated 10/30/97
Helen & Richard Spalding Revocable Trust
Dan & Lisa Spiegelman
Todd J. Lorenz
Leslie M. McEvoy
John P. and Rita M. McLaughlin
Mark F. McLaughlin
Mauri Y. Okamoto-Kearney and Terrance J.P. Kearney
Patricia Oto
Michael F. Burns
William F. and Heidi V. Burns
William J. Burns Living Trust
Jean and Douglas Carlson
Mark Weiss
Michael Sandifer
Emma Stableford
Amerindo Technology Fund
Amerindo Internet Growth Fund Ltd.
Gilead Sciences, Inc.
Pfizer Ireland Pharmaceuticals

                                      S-3<PAGE>

                                                                    EXHIBIT 10.1

                          EYETECH PHARMACEUTICALS, INC.

                                 2001 STOCK PLAN

                            ADOPTED ON APRIL 4, 2001

<PAGE>

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                                   PAGE NO.
                                                                                                   --------
<S>                                                                                                <C>
SECTION 1.  ESTABLISHMENT AND PURPOSE..........................................................       1

SECTION 2.  ADMINISTRATION.....................................................................       1

     (a)      Committees of the Board of Directors.............................................       1
     (b)      Authority of the Board of Directors..............................................       1

SECTION 3.  ELIGIBILITY........................................................................       1

     (a)      General Rule.....................................................................       1
     (b)      Ten-Percent Stockholders.........................................................       1

SECTION 4.  STOCK SUBJECT TO PLAN..............................................................       2

     (a)      Basic Limitation.................................................................       2
     (b)      Additional Shares................................................................       2

SECTION 5.  TERMS AND CONDITIONS OF AWARDS OR SALES............................................       2

     (a)      Stock Purchase Agreement.........................................................       2
     (b)      Duration of Offers and Nontransferability of Rights..............................       2
     (c)      Purchase Price...................................................................       2
     (d)      Withholding Taxes................................................................       2
     (e)      Restrictions on Transfer of Shares and Minimum Vesting...........................       3

SECTION 6.  TERMS AND CONDITIONS OF OPTIONS....................................................       3

     (a)      Stock Option Agreement...........................................................       3
     (b)      Number of Shares.................................................................       3
     (c)      Exercise Price...................................................................       3
     (d)      Exercisability...................................................................       3
     (e)      Accelerated Exercisability.......................................................       4
     (f)      Basic Term.......................................................................       4
     (g)      Termination of Service (Except by Death).........................................       4
     (h)      Leaves of Absence................................................................       4
     (i)      Death of Optionee................................................................       5
     (j)      Restrictions on Transfer of Shares and Minimum Vesting...........................       5
     (k)      Transferability of Options.......................................................       5
     (l)      Withholding Taxes................................................................       5
     (m)      No Rights as a Stockholder.......................................................       6
     (n)      Modification, Extension and Assumption of Options................................       6
</TABLE>

                                       i

<PAGE>

<TABLE>
<S>                                                                                                    <C>
SECTION 7.  PAYMENT FOR SHARES.................................................................        6

     (a)      General Rule.....................................................................        6
     (b)      Surrender of Stock...............................................................        6
     (c)      Services Rendered................................................................        6
     (d)      Promissory Note..................................................................        6
     (e)      Exercise/Sale....................................................................        7
     (f)      Exercise/Pledge..................................................................        7

SECTION 8.  ADJUSTMENT OF SHARES...............................................................        7

     (a)      General..........................................................................        7
     (b)      Mergers and Consolidations.......................................................        7
     (c)      Reservation of Rights............................................................        7

SECTION 9.  SECURITIES LAW REQUIREMENTS........................................................        8

     (a)      General..........................................................................        8
     (b)      Financial Reports................................................................        8

SECTION 10.  NO RETENTION RIGHTS...............................................................        8

SECTION 11.  DURATION AND AMENDMENTS...........................................................        8

     (a)      Term of the Plan.................................................................        8
     (b)      Right to Amend or Terminate the Plan.............................................        9
     (c)      Effect of Amendment or Termination...............................................        9

SECTION 12.  DEFINITIONS.......................................................................        9
</TABLE>

                                       i

<PAGE>

                  EYETECH PHARMACEUTICALS, INC. 2001 STOCK PLAN

SECTION 1. ESTABLISHMENT AND PURPOSE.

                  The purpose of the Plan is to offer selected persons an
opportunity to acquire a proprietary interest in the success of the Company, or
to increase such interest, by purchasing Shares of the Company's Stock. The Plan
provides both for the direct award or sale of Shares and for the grant of
Options to purchase Shares. Options granted under the Plan may include
Nonstatutory Options as well as ISOs intended to qualify under Section 422 of
the Code.

                  Capitalized terms are defined in Section 12.

SECTION 2. ADMINISTRATION.

                  (a)      COMMITTEES OF THE BOARD OF DIRECTORS. The Plan may be
administered by one or more Committees. Each Committee shall consist of one or
more members of the Board of Directors who have been appointed by the Board of
Directors. Each Committee shall have such authority and be responsible for such
functions as the Board of Directors has assigned to it. If no Committee has been
appointed, the entire Board of Directors shall administer the Plan. Any
reference to the Board of Directors in the Plan shall be construed as a
reference to the Committee (if any) to whom the Board of Directors has assigned
a particular function.

                  (b)      AUTHORITY OF THE BOARD OF DIRECTORS. Subject to the
provisions of the Plan, the Board of Directors shall have full authority and
discretion to take any actions it deems necessary or advisable for the
administration of the Plan. All decisions, interpretations and other actions of
the Board of Directors shall be final and binding on all Purchasers, all
Optionees and all persons deriving their rights from a Purchaser or Optionee.

SECTION 3. ELIGIBILITY.

                  (a)      GENERAL RULE. Only Employees, Outside Directors and
Consultants shall be eligible for the grant of Nonstatutory Options or the
direct award or sale of Shares. Only Employees shall be eligible for the grant
of ISOs.

                  (b)      TEN-PERCENT STOCKHOLDERS. A person who owns more than
10% of the total combined voting power of all classes of outstanding stock of
the Company, its Parent or any of its Subsidiaries shall not be eligible for
designation as an Optionee or Purchaser unless (i) the Exercise Price is at
least 110% of the Fair Market Value of a Share on the date of grant, (ii) the
Purchase Price (if any) is at least 100% of the Fair Market Value of a Share and
(iii) in the case of an ISO, such ISO by its terms is not exercisable after the
expiration of five years from the date of grant. For purposes of this Subsection
(b), in determining stock ownership, the attribution rules of Section 424(d) of
the Code shall be applied.

<PAGE>

SECTION 4. STOCK SUBJECT TO PLAN.

                  (a)      BASIC LIMITATION. Shares offered under the Plan may
be authorized but unissued Shares or treasury Shares. The aggregate number of
Shares that may be issued under the Plan (upon exercise of Options or other
rights to acquire Shares) shall not exceed 8,175,000 Shares, subject to
adjustment pursuant to Section 8. The number of Shares that are subject to
Options or other rights outstanding at any time under the Plan shall not exceed
the number of Shares that then remain available for issuance under the Plan. The
Company, during the term of the Plan, shall at all times reserve and keep
available sufficient Shares to satisfy the requirements of the Plan.

                  (b)      ADDITIONAL SHARES. In the event that any outstanding
Option or other right for any reason expires or is canceled or otherwise
terminated, the Shares allocable to the unexercised portion of such Option or
other right shall again be available for the purposes of the Plan. In the event
that Shares issued under the Plan are reacquired by the Company pursuant to any
forfeiture provision, right of repurchase or right of first refusal, such Shares
shall again be available for the purposes of the Plan, except that the aggregate
number of Shares which may be issued upon the exercise of ISOs shall in no event
exceed 8,175,000 Shares (subject to adjustment pursuant to Section 8).

SECTION 5. TERMS AND CONDITIONS OF AWARDS OR SALES.

                  (a)      STOCK PURCHASE AGREEMENT. Each award or sale of
Shares under the Plan (other than upon exercise of an Option) shall be evidenced
by a Stock Purchase Agreement between the Purchaser and the Company. Such award
or sale shall be subject to all applicable terms and conditions of the Plan and
may be subject to any other terms and conditions which are not inconsistent with
the Plan and which the Board of Directors deems appropriate for inclusion in a
Stock Purchase Agreement. The provisions of the various Stock Purchase
Agreements entered into under the Plan need not be identical.

                  (b)      DURATION OF OFFERS AND NONTRANSFERABILITY OF RIGHTS.
Any right to acquire Shares under the Plan (other than an Option) shall
automatically expire if not exercised by the Purchaser within 30 days after the
grant of such right was communicated to the Purchaser by the Company. Such right
shall not be transferable and shall be exercisable only by the Purchaser to whom
such right was granted.

                  (c)      PURCHASE PRICE. The Purchase Price of Shares to be
offered under the Plan shall not be less than 85% of the Fair Market Value of
such Shares, and a higher percentage may be required by Section 3(b). Subject to
the preceding sentence, the Board of Directors shall determine the Purchase
Price at its sole discretion. The Purchase Price shall be payable in a form
described in Section 7.

                  (d)      WITHHOLDING TAXES. As a condition to the purchase of
Shares, the Purchaser shall make such arrangements as the Board of Directors may
require for the satisfaction of any federal, state, local or foreign withholding
tax obligations that may arise in connection with such purchase.

<PAGE>

                  (e)      RESTRICTIONS ON TRANSFER OF SHARES AND MINIMUM
VESTING. Any Shares awarded or sold under the Plan shall be subject to such
special forfeiture conditions, rights of repurchase, rights of first refusal and
other transfer restrictions as the Board of Directors may determine. Such
restrictions shall be set forth in the applicable Stock Purchase Agreement and
shall apply in addition to any restrictions that may apply to holders of Shares
generally. In the case of a Purchaser who is not an officer of the Company, an
Outside Director or a Consultant:

                           (i)      Any right to repurchase the Purchaser's
         Shares at the original Purchase Price (if any) upon termination of the
         Purchaser's Service shall lapse at least as rapidly as 20% per year
         over the five-year period commencing on the date of the award or sale
         of the Shares;

                           (ii)     Any such right may be exercised only for
         cash or for cancellation of indebtedness incurred in purchasing the
         Shares; and

                           (iii)    Any such right may be exercised only within
         90 days after the termination of the Purchaser's Service.

SECTION 6. TERMS AND CONDITIONS OF OPTIONS.

                  (a)      STOCK OPTION AGREEMENT. Each grant of an Option under
the Plan shall be evidenced by a Stock Option Agreement between the Optionee and
the Company. Such Option shall be subject to all applicable terms and conditions
of the Plan and may be subject to any other terms and conditions which are not
inconsistent with the Plan and which the Board of Directors deems appropriate
for inclusion in a Stock Option Agreement. The provisions of the various Stock
Option Agreements entered into under the Plan need not be identical.

                  (b)      NUMBER OF SHARES. Each Stock Option Agreement shall
specify the number of Shares that are subject to the Option and shall provide
for the adjustment of such number in accordance with Section 8. The Stock Option
Agreement shall also specify whether the Option is an ISO or a Nonstatutory
Option.

                  (c)      EXERCISE PRICE. Each Stock Option Agreement shall
specify the Exercise Price. The Exercise Price of an ISO shall not be less than
100% of the Fair Market Value of a Share on the date of grant, and a higher
percentage may be required by Section 3(b). The Exercise Price of a Nonstatutory
Option shall not be less than 85% of the Fair Market Value of a Share on the
date of grant, and a higher percentage may be required by Section 3(b). Subject
to the preceding two sentences, the Exercise Price under any Option shall be
determined by the Board of Directors at its sole discretion. The Exercise Price
shall be payable in a form described in Section 7.

                  (d)      EXERCISABILITY. Each Stock Option Agreement shall
specify the date when all or any installment of the Option is to become
exercisable. In the case of an Optionee who is not an officer of the Company, an
Outside Director or a Consultant, an Option shall become exercisable at least as
rapidly as 20% per year over the five-year period commencing on the date of
grant. Subject to the preceding sentence, the Board of Directors shall determine
the exercisability provisions of any Stock Option Agreement at its sole
discretion.

<PAGE>

                  (e)      ACCELERATED EXERCISABILITY. Unless the applicable
Stock Option Agreement provides otherwise, all of an Optionee's Options shall
become exercisable in full if (i) the Company is subject to a Change in Control
before the Optionee's Service terminates, (ii) such Options do not remain
outstanding, (iii) such Options are not assumed by the surviving corporation or
its parent and (iv) the surviving corporation or its parent does not substitute
options with substantially the same terms for such Options.

                  (f)      BASIC TERM. The Stock Option Agreement shall specify
the term of the Option. The term shall not exceed 10 years from the date of
grant, and a shorter term may be required by Section 3(b). Subject to the
preceding sentence, the Board of Directors at its sole discretion shall
determine when an Option is to expire.

                  (g)      TERMINATION OF SERVICE (EXCEPT BY DEATH). If an
Optionee's Service terminates for any reason other than the Optionee's death,
then the Optionee's Options shall expire on the earliest of the following
occasions:

                           (i)      The expiration date determined pursuant to
         Subsection (f) above;

                           (ii)     The date three months after the termination
         of the Optionee's Service for any reason other than Disability, or such
         later date as the Board of Directors may determine; or

                           (iii)    The date six months after the termination of
         the Optionee's Service by reason of Disability, or such later date as
         the Board of Directors may determine.

The Optionee may exercise all or part of the Optionee's Options at any time
before the expiration of such Options under the preceding sentence, but only to
the extent that such Options had become exercisable before the Optionee's
Service terminated (or became exercisable as a result of the termination) and
the underlying Shares had vested before the Optionee's Service terminated (or
vested as a result of the termination). The balance of such Options shall lapse
when the Optionee's Service terminates. In the event that the Optionee dies
after the termination of the Optionee's Service but before the expiration of the
Optionee's Options, all or part of such Options may be exercised (prior to
expiration) by the executors or administrators of the Optionee's estate or by
any person who has acquired such Options directly from the Optionee by
beneficiary designation, bequest or inheritance, but only to the extent that
such Options had become exercisable before the Optionee's Service terminated (or
became exercisable as a result of the termination) and the underlying Shares had
vested before the Optionee's Service terminated (or vested as a result of the
termination).

                  (h)      LEAVES OF ABSENCE. For purposes of Subsection (g)
above, Service shall be deemed to continue while the Optionee is on a bona fide
leave of absence, if such leave was approved by the Company in writing and if
continued crediting of Service for this purpose is expressly required by the
terms of such leave or by applicable law (as determined by the Company).

<PAGE>

                  (i)      DEATH OF OPTIONEE. If an Optionee dies while the
Optionee is in Service, then the Optionee's Options shall expire on the earlier
of the following dates:

                           (i)      The expiration date determined pursuant to
         Subsection (f) above; or

                           (ii)     The date 12 months after the Optionee's
         death, or such later date as the Board of Directors may determine.

All or part of the Optionee's Options may be exercised at any time before the
expiration of such Options under the preceding sentence by the executors or
administrators of the Optionee's estate or by any person who has acquired such
Options directly from the Optionee by beneficiary designation, bequest or
inheritance, but only to the extent that such Options had become exercisable
before the Optionee's death (or became exercisable as a result of the death) and
the underlying Shares had vested before the Optionee's death (or vested as a
result of the Optionee's death). The balance of such Options shall lapse when
the Optionee dies.

                  (j)      RESTRICTIONS ON TRANSFER OF SHARES AND MINIMUM
VESTING. Any Shares issued upon exercise of an Option shall be subject to such
special forfeiture conditions, rights of repurchase, rights of first refusal and
other transfer restrictions as the Board of Directors may determine. Such
restrictions shall be set forth in the applicable Stock Option Agreement and
shall apply in addition to any restrictions that may apply to holders of Shares
generally. In the case of an Optionee who is not an officer of the Company, an
Outside Director or a Consultant:

                           (i)      Any right to repurchase the Optionee's
         Shares at the original Exercise Price upon termination of the
         Optionee's Service shall lapse at least as rapidly as 20% per year over
         the five-year period commencing on the date of the option grant;

                           (ii)     Any such right may be exercised only for
         cash or for cancellation of indebtedness incurred in purchasing the
         Shares; and

                           (iii)    Any such right may be exercised only within
         90 days after the later of (A) the termination of the Optionee's
         Service or (B) the date of the option exercise.

                  (k)      TRANSFERABILITY OF OPTIONS. An Option shall be
         transferable by the Optionee only by (i) a beneficiary designation,
         (ii) a will or (iii) the laws of descent and distribution, except as
         provided in the next sentence. If the applicable Stock Option Agreement
         so provides, an NSO shall also be transferable by the Optionee by (i) a
         gift to a member of the Optionee's Immediate Family or (ii) a gift to
         an inter vivos or testamentary trust in which members of the Optionee's
         Immediate Family have a beneficial interest of more than 50% and which
         provides that such NSO is to be transferred to the beneficiaries upon
         the Optionee's death. An ISO may be exercised during the lifetime of
         the Optionee only by the Optionee or by the Optionee's guardian or
         legal representative.

                  (l)      WITHHOLDING TAXES. As a condition to the exercise of
an Option, the Optionee shall make such arrangements as the Board of Directors
may require for the satisfaction

<PAGE>

of any federal, state, local or foreign withholding tax obligations that may
arise in connection with such exercise. The Optionee shall also make such
arrangements as the Board of Directors may require for the satisfaction of any
federal, state, local or foreign withholding tax obligations that may arise in
connection with the disposition of Shares acquired by exercising an Option.

                  (m)      NO RIGHTS AS A STOCKHOLDER. An Optionee, or a
transferee of an Optionee, shall have no rights as a stockholder with respect to
any Shares covered by the Optionee's Option until such person becomes entitled
to receive such Shares by filing a notice of exercise and paying the Exercise
Price pursuant to the terms of such Option.

                  (n)      MODIFICATION, EXTENSION AND ASSUMPTION OF OPTIONS.
Within the limitations of the Plan, the Board of Directors may modify, extend or
assume outstanding Options or may accept the cancellation of outstanding Options
(whether granted by the Company or another issuer) in return for the grant of
new Options for the same or a different number of Shares and at the same or a
different Exercise Price. The foregoing notwithstanding, no modification of an
Option shall, without the consent of the Optionee, impair the Optionee's rights
or increase the Optionee's obligations under such Option.

SECTION 7. PAYMENT FOR SHARES.

                  (a)      GENERAL RULE. The entire Purchase Price or Exercise
Price of Shares issued under the Plan shall be payable in cash or cash
equivalents at the time when such Shares are purchased, except as otherwise
provided in this Section 7.

                  (b)      SURRENDER OF STOCK. To the extent that a Stock Option
Agreement so provides, all or any part of the Exercise Price may be paid by
surrendering, or attesting to the ownership of, Shares that are already owned by
the Optionee. Such Shares shall be surrendered to the Company in good form for
transfer and shall be valued at their Fair Market Value on the date when the
Option is exercised. The Optionee shall not surrender, or attest to the
ownership of, Shares in payment of the Exercise Price if such action would cause
the Company to recognize compensation expense (or additional compensation
expense) with respect to the Option for financial reporting purposes.

                  (c)      SERVICES RENDERED. At the discretion of the Board of
Directors, Shares may be awarded under the Plan in consideration of services
rendered to the Company, a Parent or a Subsidiary prior to the award.

                  (d)      PROMISSORY NOTE. To the extent that a Stock Option
Agreement or Stock Purchase Agreement so provides, all or a portion of the
Exercise Price or Purchase Price (as the case may be) of Shares issued under the
Plan may be paid with a full-recourse promissory note. However, the par value of
the Shares, if newly issued, shall be paid in cash or cash equivalents. The
Shares shall be pledged as security for payment of the principal amount of the
promissory note and interest thereon. The interest rate payable under the terms
of the promissory note shall not be less than the minimum rate (if any) required
to avoid the imputation of additional interest under the Code. Subject to the
foregoing, the Board of Directors (at its sole discretion) shall specify the
term, interest rate, amortization requirements (if any) and other provisions of
such note.

<PAGE>

                  (e)      EXERCISE/SALE. To the extent that a Stock Option
Agreement so provides, and if Stock is publicly traded, payment may be made all
or in part by the delivery (on a form prescribed by the Company) of an
irrevocable direction to a securities broker approved by the Company to sell
Shares and to deliver all or part of the sales proceeds to the Company in
payment of all or part of the Exercise Price and any withholding taxes.

                  (f)      EXERCISE/PLEDGE. To the extent that a Stock Option
Agreement so provides, and if Stock is publicly traded, payment may be made all
or in part by the delivery (on a form prescribed by the Company) of an
irrevocable direction to pledge Shares to a securities broker or lender approved
by the Company, as security for a loan, and to deliver all or part of the loan
proceeds to the Company in payment of all or part of the Exercise Price and any
withholding taxes.

SECTION 8. ADJUSTMENT OF SHARES.

                  (a)      GENERAL. In the event of a subdivision of the
outstanding Stock, a declaration of a dividend payable in Shares, a declaration
of an extraordinary dividend payable in a form other than Shares in an amount
that has a material effect on the Fair Market Value of the Stock, a combination
or consolidation of the outstanding Stock into a lesser number of Shares, a
recapitalization, a spin-off, a reclassification or a similar occurrence, the
Board of Directors shall make appropriate adjustments in one or more of (i) the
number of Shares available for future grants under Section 4, (ii) the number of
Shares covered by each outstanding Option or (iii) the Exercise Price under each
outstanding Option.

                  (b)      MERGERS AND CONSOLIDATIONS. In the event that the
Company is a party to a merger or consolidation, outstanding Options shall be
subject to the agreement of merger or consolidation. Such agreement shall
provide for:

                           (i)      The continuation of such outstanding Options
         by the Company (if the Company is the surviving corporation);

                           (ii)     The assumption of the Plan and such
         outstanding Options by the surviving corporation or its parent;

                           (iii)    The substitution by the surviving
         corporation or its parent of options with substantially the same terms
         for such outstanding Options;

                           (iv)     The full exercisability of such outstanding
         Options and full vesting of the Shares subject to such Options,
         followed by the cancellation of such Options; or

                           (v)      The settlement of the full value of such
         outstanding Options (whether or not then exercisable) in cash or cash
         equivalents, followed by the cancellation of such Options.

                  (c)      RESERVATION OF RIGHTS. Except as provided in this
Section 8, an Optionee or Purchaser shall have no rights by reason of (i) any
subdivision or consolidation of shares of

<PAGE>

stock of any class, (ii) the payment of any dividend or (iii) any other increase
or decrease in the number of shares of stock of any class. Any issuance by the
Company of shares of stock of any class, or securities convertible into shares
of stock of any class, shall not affect, and no adjustment by reason thereof
shall be made with respect to, the number or Exercise Price of Shares subject to
an Option. The grant of an Option pursuant to the Plan shall not affect in any
way the right or power of the Company to make adjustments, reclassifications,
reorganizations or changes of its capital or business structure, to merge or
consolidate or to dissolve, liquidate, sell or transfer all or any part of its
business or assets.

SECTION 9. SECURITIES LAW REQUIREMENTS.

                  (a)      GENERAL. Shares shall not be issued under the Plan
unless the issuance and delivery of such Shares comply with (or are exempt from)
all applicable requirements of law, including (without limitation) the
Securities Act of 1933, as amended, the rules and regulations promulgated
thereunder, state securities laws and regulations, and the regulations of any
stock exchange or other securities market on which the Company's securities may
then be traded.

                  (b)      FINANCIAL REPORTS. The Company each year shall
furnish to Optionees, Purchasers and stockholders who have received Stock under
the Plan its balance sheet and income statement, unless such Optionees,
Purchasers or stockholders are key Employees whose duties with the Company
assure them access to equivalent information. Such balance sheet and income
statement need not be audited.

SECTION 10. NO RETENTION RIGHTS.

                  Nothing in the Plan or in any right or Option granted under
the Plan shall confer upon the Purchaser or Optionee any right to continue in
Service for any period of specific duration or interfere with or otherwise
restrict in any way the rights of the Company (or any Parent or Subsidiary
employing or retaining the Purchaser or Optionee) or of the Purchaser or
Optionee, which rights are hereby expressly reserved by each, to terminate his
or her Service at any time and for any reason, with or without cause.

SECTION 11. DURATION AND AMENDMENTS.

                  (a)      TERM OF THE PLAN. The Plan, as set forth herein,
shall become effective on the date of its adoption by the Board of Directors,
subject to the approval of the Company's stockholders. If the stockholders fail
to approve the Plan (or the most recent increase in the number of Shares
reserved under Section 4) within 12 months after its adoption by the Board of
Directors, then any grants of Options or sales or awards of Shares that have
already occurred under the Plan (or in reliance on such increase) shall be
rescinded, and no additional grants, sales or awards shall be made thereafter
under the Plan. The Plan shall terminate automatically 10 years after the later
of (i) its adoption by the Board of Directors or (ii) the most recent increase
in the number of Shares reserved under Section 4 that was approved by the
Company's stockholders. The Plan may be terminated on any earlier date pursuant
to Subsection (b) below.

<PAGE>

                  (b)      RIGHT TO AMEND OR TERMINATE THE PLAN. The Board of
Directors may amend, suspend or terminate the Plan at any time and for any
reason; provided, however, that any amendment of the Plan which increases the
number of Shares available for issuance under the Plan (except as provided in
Section 8), or which materially changes the class of persons who are eligible
for the grant of ISOs, shall be subject to the approval of the Company's
stockholders. Stockholder approval shall not be required for any other amendment
of the Plan.

                  (c)      EFFECT OF AMENDMENT OR TERMINATION. No Shares shall
be issued or sold under the Plan after the termination thereof, except upon
exercise of an Option granted prior to such termination. The termination of the
Plan, or any amendment thereof, shall not affect any Share previously issued or
any Option previously granted under the Plan.

SECTION 12. DEFINITIONS.

                  (a)      "BOARD OF DIRECTORS" shall mean the Board of
Directors of the Company, as constituted from time to time.

                  (b)      "CHANGE IN CONTROL" shall mean:

                           (i)     The consummation of a merger or
         consolidation of the Company with or into another entity or any other
         corporate reorganization, if persons who were not stockholders of the
         Company immediately prior to such merger, consolidation or other
         reorganization own immediately after such merger, consolidation or
         other reorganization 50% or more of the voting power of the outstanding
         securities of each of (A) the continuing or surviving entity and (B)
         any direct or indirect parent corporation of such continuing or
         surviving entity; or

                           (ii)    The sale, transfer or other disposition of
         all or substantially all of the Company's assets.

A transaction shall not constitute a Change in Control if its sole purpose is to
change the state of the Company's incorporation or to create a holding company
that will be owned in substantially the same proportions by the persons who held
the Company's securities immediately before such transaction.

                  (c)      "CODE" shall mean the Internal Revenue Code of 1986,
as amended.

                  (d)      "COMMITTEE" shall mean a committee of the Board of
Directors, as described in Section 2(a).

                  (e)      "COMPANY" shall mean Eyetech Pharmaceuticals, Inc., a
Delaware corporation.

                  (f)      "CONSULTANT" shall mean a person who performs bona
fide services for the Company, a Parent or a Subsidiary as a consultant or
advisor, excluding Employees and Outside Directors.

<PAGE>

                  (g)      "DISABILITY" shall mean that the Optionee is unable
to engage in any substantial gainful activity by reason of any medically
determinable physical or mental impairment.

                  (h)      "EMPLOYEE" shall mean any individual who is a
common-law employee of the Company, a Parent or a Subsidiary.

                  (i)      "EXERCISE PRICE" shall mean the amount for which one
Share may be purchased upon exercise of an Option, as specified by the Board of
Directors in the applicable Stock Option Agreement.

                  (j)      "FAIR MARKET VALUE" shall mean the fair market value
of a Share, as determined by the Board of Directors in good faith. Such
determination shall be conclusive and binding on all persons.

                  (k)      "IMMEDIATE FAMILY" shall mean any child, stepchild,
grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law,
father-in-law, son-in-law, daughter-in-law, brother-in-law or sister-in-law and
shall include adoptive relationships.

                  (l)      "ISO" shall mean an employee incentive stock option
described in Section 422(b) of the Code.

                  (m)      "NONSTATUTORY OPTION" shall mean a stock option not
described in Sections 422(b) or 423(b) of the Code.

                  (n)      "OPTION" shall mean an ISO or Nonstatutory Option
granted under the Plan and entitling the holder to purchase Shares.

                  (o)      "OPTIONEE" shall mean a person who holds an Option.

                  (p)      "OUTSIDE DIRECTOR" shall mean a member of the Board
of Directors who is not an Employee.

                  (q)      "PARENT" shall mean any corporation (other than the
Company) in an unbroken chain of corporations ending with the Company, if each
of the corporations other than the Company owns stock possessing 50% or more of
the total combined voting power of all classes of stock in one of the other
corporations in such chain. A corporation that attains the status of a Parent on
a date after the adoption of the Plan shall be considered a Parent commencing as
of such date.

                  (r)      "PLAN" shall mean this Eyetech Pharmaceuticals, Inc.
2001 Stock Plan.

                  (s)      "PURCHASE PRICE" shall mean the consideration for
which one Share may be acquired under the Plan (other than upon exercise of an
Option), as specified by the Board of Directors.

                  (t)      "PURCHASER" shall mean a person to whom the Board of
Directors has offered the right to acquire Shares under the Plan (other than
upon exercise of an Option).

<PAGE>

                  (u)      "SERVICE" shall mean service as an Employee, Outside
Director or Consultant.

                  (v)      "SHARE" shall mean one share of Stock, as adjusted in
accordance with Section 8 (if applicable).

                  (w)      "STOCK" shall mean the Common Stock of the Company,
with a par value of $0.01 per Share.

                  (x)      "STOCK OPTION AGREEMENT" shall mean the agreement
between the Company and an Optionee that contains the terms, conditions and
restrictions pertaining to the Optionee's Option.

                  (y)      "STOCK PURCHASE AGREEMENT" shall mean the agreement
between the Company and a Purchaser who acquires Shares under the Plan that
contains the terms, conditions and restrictions pertaining to the acquisition of
such Shares.

                  (z)      "SUBSIDIARY" shall mean any corporation (other than
the Company) in an unbroken chain of corporations beginning with the Company, if
each of the corporations other than the last corporation in the unbroken chain
owns stock possessing 50% or more of the total combined voting power of all
classes of stock in one of the other corporations in such chain. A corporation
that attains the status of a Subsidiary on a date after the adoption of the Plan
shall be considered a Subsidiary commencing as of such date.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}]]